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ABSTRACT 
 
Development of Cell Culture Models for Age-related Macular Degeneration 
 
by 
 
David Forest 
 
Age-related macular degeneration (AMD) is a blinding disorder which affects millions of 
elderly people worldwide.  AMD etiology is still not completely understood, and treatments 
for the most common form of the disease, geographic atrophy, are lacking.  There are many 
animal models for AMD.  Yet, no single model completely recapitulates the disorder.  Cell 
culture models are another method used to recreate certain aspects of the disease.  However, 
cell-based “disease-in-a-dish” models are currently not well developed.  This dissertation 
focuses on the development and applications of new cell culture based models for macular 
degeneration. 
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Chapter I 
 
Cellular Models and Therapies for Age-related Macular Degeneration 
 
 
Abstract 
Age-related macular degeneration (AMD) is a complex neurodegenerative visual disorder 
that causes profound physical and psychosocial effects.  Visual impairment in AMD is 
caused by the loss of retinal pigmented epithelial (RPE) cells and the light-sensitive 
photoreceptor cells that they support.  There is currently no effective treatment for the most 
common form of this disease.  A new approach to treating AMD involves the transplantation 
of RPE cells derived from either human embryonic or induced pluripotent stem cells.  
Multiple clinical trials are being initiated using a variety of approaches.  Although there are 
many available, AMD research is hampered by a lack of animal models that recapitulate all 
aspects of the disease.  The use of cultured RPE cells in AMD research is well established.  
Indeed, some of the more recently described RPE-based models show promise for 
investigating the molecular mechanisms of AMD and for screening drug candidates.  Here 
we discuss innovative cell culture models of AMD and emerging stem cell-based therapies 
for the treatment of this vision-robbing disease.  
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Introduction  
AMD – age-related macular degeneration – is a leading cause of blindness for millions of 
people over the age of 60.  The disease is associated not only with visual impairment, but 
also with high rates of depression, anxiety, and emotional distress (Berman and Brodaty, 
2006).  Visual dysfunction in AMD is associated with the degeneration of retinal pigmented 
epithelial (RPE) cells and of the light-sensing photoreceptor cells that they support.  
Degeneration of RPE cells in AMD appears to begin with impaired clearance of cellular 
waste material.  This leads to a state of chronic inflammation in the eye, and eventually to the 
formation of abnormal deposits called drusen, which impairs the function of RPE cells (Fig. 
1.1).  
 Healthy adult RPE cells form a tightly interconnected sheet of cells positioned 
between the photoreceptors and a rich vascular layer, the choroid (or choriocapillaris).  This 
arrangement creates a semi-permeable barrier that allows the RPE to selectively transport 
nutrients from the blood supply to the outer layers of the retina (Hewitt and Adler 1989).  
Other important features of the RPE will be highlighted in the next section which focuses on 
the pathology of AMD.  The macula (or macula lutea – “yellow spot”) is a specialized 
anatomical feature of the retina that is responsible for focused, high-resolution color vision.  
A progressive loss of this fine acuity central vision is characteristic of AMD.     
 As discussed in more detail below, there are two main forms of the disorder: wet 
AMD, for which some treatment options exist, and dry AMD, which is the most common 
form of the disease.  Dry AMD is a candidate for emerging cellular transplantation 
therapeutics because there are currently no clinical treatments available.  Several different 
cell types are being considered for therapeutic transplantation, including stem cells isolated  
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Fig. 1.1. Drusen deposits under RPE cells of an AMD patient. Confocal microscopy image of 
retinal tissue from an 82-year-old female patient with a history of AMD.  Drusen deposits are 
implicated in the degeneration of retinal pigmented epithelial (RPE) cells.  Here, a cell 
membrane marker in grey shows degraded RPE cells overlying drusen. Areas of complement 
activation within the drusen and around the blood vessels are indicated in red.  Nuclei are 
stained blue.  Scale bar (upper left): 20 micrometers.   
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from umbilical cord, neural progenitor cells, and RPE cells derived from pluripotent stem 
cells.  Several of these therapies are currently in, or are rapidly approaching, clinical trials 
(Table 1.1, adapted from Bharti et al. 2014).  Pluripotent stem cells include human 
embryonic (hESCs) and induced pluripotent (iPSCs) stem cells.Both have the potential to 
become almost any cell type in the body (Thomson et al. 1998; Takahashi and Yamanaka 
2006).  They also serve as model systems of early developmental stages, and as source 
material for stem cell-based therapies (Meyer et al., 2011).   
 In anticipation of their therapeutic use, multiple groups have derived RPE cells from 
both pluripotent cell types (Buchholz et al., 2009; Hirami et al., 2009; Kamao et al., 2014; 
Klimanskaya et al., 2004; Krohne et al., 2012).  RPE cells derived from human embryonic 
stem cells (hESC-RPE) are currently being used in clinical trials for macular degeneration.  
In these trials, a suspension of up to 150,000 cells was injected into an area between the 
degenerating photoreceptor cell and RPE cell layers.  A recent follow-up study of the 18 
patients involved in the trials revealed no serious safety issues related to the transplanted 
cells (Schwartz et al., 2014).  Implantation of a single layer of stem cell-derived RPE is 
another treatment approach currently under development (Carr et al., 2013, Idelson et al., 
2009).  Recently, a Japanese woman in her 70s was the first person to receive a transplanted 
layer of iPSC-RPE derived from her own skin cells (Cyranoski, 2014). 
 In this review, we first summarize the main pathological features and disease 
mechanisms that are characteristic of AMD.  Then, we introduce some of the innovative cell-
based models in development.  Finally, we discuss the potential of stem cell-based 
therapeutics for the treatment of AMD.  Animal models for AMD, while useful in some 
respects, fall short of recapitulating all aspects of the disease.  An exhaustive summary of the 
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many animal models currently in use is beyond the scope of this review, which focuses on 
cell-culture models.  More information on animal models of AMD may be found in one of 
the many papers on the subject (see Pennesi et al., 2012, Zeiss 2010).     
 
The Pathology of AMD   
One way that RPE cells support visual function is by ingesting and disposing of 
photoreceptor cell outer segments. Outer segments are the site of phototransduction, where 
light energy is converted into an electrical signal.  They are constantly produced by 
photoreceptor cells and the older segments are discarded as waste material on a daily cycle.  
The RPE cells internalize the old segments and recycle the light-sensitive molecule retinol 
back to the photoreceptors.  Another critical function of the RPE cells is to transport nutrients 
from the blood supply to the photoreceptors.  As highlighted above and illustrated in Figure 
1.1, toxic deposits called drusen accumulate in the macula of AMD patients.  Drusen are 
formed by cellular debris that is trapped between the single layer of RPE cells and Bruch’s 
membrane, a specialized extracellular matrix to which the RPE adheres.  The debris appears 
to act as a chronic inflammatory stimulus that initiates the process of drusen formation 
(Johnson et al., 2001).  Drusen can eventually destroy RPE cells, and the resulting loss or 
disruption of RPE support functions consequently leads to photoreceptor degeneration.  
AMD primarily affects central vision, while some peripheral vision remains.   
 Advanced age is the primary risk factor for AMD.  Physiological changes that 
generally occur past the age of 60 can impair cellular function in those at risk of the disease 
(Demontis et al., 2013).  There are several other AMD-associated risk factors that include 
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genetic susceptibility, smoking, and diet (McCarty et al. 2001).  The disease typically 
manifests in two different forms that are identified as wet (exudative) or dry (atrophic) AMD.   
 Wet AMD is currently treated with ocular injections that delay the abnormal growth 
of blood vessels into the retina, which characterizes this form of the disease.  Current wet 
AMD drug treatments focus on inhibiting vascular endothelial growth factor (VEGF), which 
stimulates blood vessel production (Table 1.1).  Recently, the possibility of adverse side 
effects due to ocular administration of VEGF has received attention.  A specific role for 
VEGF in the regulation of RPE function and the long-term effects of anti-VEGF treatments 
in humans are unknown (Ablonczy et al., 2011).  But, in mouse models, prolonged treatment 
with anti-VEGF therapy correlates with increased death of photoreceptors and their 
supporting cells within the retina (Ford et al., 2012; Saint-Geniez et al., 2008).   
 
Table 1.1. Currently available drug treatments for wet age related macular degeneration  
Therapy Developer Status (2015) Action 
Ranibizumab (Lucentis) 
Bevacizumab (Avastin) 
Pegaptanib (Macugen) 
Aflibercept (Eylea) 
Genentech 
Genentech 
Gilead/OS/Pfizer 
Regeneron 
FDA approved 
FDA approved (cancer) 
FDA approved 
FDA approved 
Anti-VEGF antibody 
Anti-VEGF antibody 
Anti-VEGF RNA aptamer 
Fusion protein (VEGF / antibody) 
Abbreviations: FDA: Food and Drug Administration (U.S.); VEGF = vascular endothelial growth factor. 
Source: Ratner (2014). 
 
 Most of those afflicted with advanced AMD have the dry form of the disease, which 
is currently untreatable.  In this form, the disease frequently reaches an end-stage condition 
called geographic atrophy (GA).  GA is characterized by a progressive loss of photoreceptor 
cells, RPE cells, and the underlying blood vessels (Sunness 1999).  GA begins with small, 
focal lesions that typically form around the macula and eventually coalesce into a large area 
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of atrophy.  This process is initially perceived as tunnel vision that, over a period of years, 
eventually consumes central vision.     
 Impaired immune system regulation might contribute to the progression of AMD.  In 
particular, disruption of the complement system is implicated in AMD development 
(Anderson et al., 2010).  The complement system is a related group of proteins that circulate 
in the bloodstream and form an integral part of the immune system.  When activated, 
complement proteins are largely responsible for pathogen recognition and removal.  
Complement activation also initiates an inflammatory response at sites of injury or infection.  
Variations in several complement system genes are associated with AMD, some of which 
might cause the complement system to be over-active, resulting in a chronic inflammatory 
condition (Kawa, et al., 2014; Hageman et al., 2005).  This abnormal inflammatory stimulus 
adversely affects RPE cells and promotes drusen formation (Jakobsdottir et al., 2008).  
However, the exact mechanism by which complement system abnormalities contribute to 
AMD development is not established (Yates et al., 2007).  Several new drug compounds that 
target the complement system are in development, but are not currently approved for clinical 
use (Table 1.2, Ambati et al., 2013).  Both the wet and dry forms of AMD might be treated 
by these newly emerging anti-complement therapies (Rohrer et al., 2010).  
 
Table 1.2. Anti-complement drugs being tested to treat dry age related macular degeneration 
Therapy Developer Status (2015) Action 
AL-78898A (compstatin) 
ARC 1905 
Eculizumab (Soliris) 
Lampalizumab (FCFD4514S) 
LFG316 
Alcon Research 
Ophthotech 
Alexion 
Genentech 
Novartis 
Phase 2 
Phase 2 
Phase 2 
Phase 2 
Phase 1 
C3 inhibitor (peptide) 
C5 inhibitor (aptamer) 
Anti-C5 antibody 
Anti-Factor D antibody 
Anti-C5 antibody 
Although this list focuses on anti-complement drugs, there are several other compounds (e.g. antioxidants, anti-
inflammatory compounds, and anti-VEGF combination therapies) that are currently in clinical trials. Sources: 
www.clinicaltrials.gov (U.S. National Institutes of Health), Ratner (2014), Ambati et al. (2013). 
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 In summary, AMD is a complex disorder that involves the interaction of genetic and 
behavioural factors – all combined with the unique anatomy of the human macula (Pennesi et 
al., 2012).  Compromised RPE function eventually leads to photoreceptor cell death and 
partial blindness that affects central vision.  There are some treatment options for wet AMD, 
but currently none for dry AMD.  Next, we discuss some of the promising new cell-based 
disease models of AMD that are currently in development. 
 
Cell-based models of AMD 
Because of the complexities of the disease and the unique features of the human eye, animal 
models, while useful in some respects, fall short of recapitulating all aspects of AMD (Zeiss 
2010).  Cell culture models are important tools used to study the physiology and pathology of 
cells and tissues, including RPE cells (Maminishkis et al., 2006; Pfeffer, 1990).  Advances in 
our understanding of AMD biology, improved cell culture systems, and the availability of 
stem cell technologies offer great potential for modeling the salient features of this disease.  
The goal of cell-based disease modeling is to relate changes observed in cultured cells to 
physiologically relevant changes in the organism (Carlson et al., 2013).  Merely obtaining a 
desired phenotype in culture does not guarantee it is of physiological relevance to disease 
(Cristofalo and Pignolo, 1995).  However, innovative new methods and technologies are 
rapidly improving the quality and utility of cell-based AMD models. 
 Cell culture models are advantageous because they are defined systems in which 
experimental conditions can be controlled and manipulated.  Also, the results are usually 
more reproducible than those from animal models (Hornof et al., 2005).  Primary cultures of 
human fetal RPE (hfRPE) are particularly effective tools in AMD research because they 
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closely model the function and metabolic activity of native RPE (Ablonczy et al., 2011).  
Thus, they have become a standard to which other RPE cell types are compared (Adijanto 
and Philip, 2014).  Other RPE cell types employed in AMD research include RPE derived 
from stem cells and the immortalized ARPE-19 cell line (Dunn et al. 1995). 
 In vivo, the apical RPE surface interfaces with retinal photoreceptors and its basal 
surface attaches to Bruch’s membrane, a specialized structure composed of collagen, laminin, 
elastin, and fibronectin (Booij et al., 2010).  This porous extracellular matrix (ECM) allows 
for selective metabolite exchange to occur between the retina and its primary blood supply, 
the choriocapillaris (Curcio and Johnson, 2013).  Cultured RPE cells require similar substrate 
attachment to attain differentiated structure and function. As such, the extracellular matrix 
that lies beneath the RPE is critical to cell-based models and therapies.  For example, purified 
ECM proteins such as collagen IV, laminin, and vitronectin differentially influence hESC-
RPE growth, pigmentation, and barrier function (Sorkio et al., 2014, Williams and Burke, 
1990).  The use of purified ECM proteins also improves the production of differentiated 
iPSC-RPE cells (Rowland et al., 2013).  
Bioengineered polymer support matrices also improve stem cell survival and 
differentiation (Enzmann et al., 2009).  In addition, support matrices promote the formation 
of a single layer of polarized RPE cells with specialized apical and basal features.  Disruption 
of this normal polarized configuration of RPE cells is implicated in retinal disease (Nasonkin 
et al., 2013).  Supporting membranes and polarized RPE monolayers are used in drug testing 
and to analyze molecular transport and secretion (Sonoda et al., 2009).   
Cell-based models also enable the experimental formation of sub-RPE deposits 
(Amin et al., 2004).  RPE cells grown on porous supports form sub-cellular deposits that 
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contain drusen-associated molecules and activated complement proteins when exposed to 
human serum (Johnson et al., 2011).  This model system was recently used as an 
experimental platform to test new peptide-based complement system inhibitors (Gorham et 
al., 2013).  The model also demonstrated that RPE cells with a defective version of Factor-H, 
a complement system regulator protein, are more susceptible to complement attack when 
exposed to a potentially toxic metabolite from photoreceptor outer segments (Radu et al., 
2014).      
Autologous, patient-derived, iPSCs can be used to generate RPE cells for disease 
modeling, personalized medicine, and patient-specific drug discovery (Mack et al., 2014; Jin 
et al., 2011).  Thus, an AMD patient’s own cells could be used to create a more accurate 
model of their disease (Phillips et al., 2014; Wahlin et al., 2014).  This approach was recently 
used to model vitelliform macular degeneration, an early onset form of Best disease (Singh et 
al., 2013).  A similar patient-derived iPSC-RPE model revealed that an AMD-associated 
gene variant disrupted the normal anti-oxidant function of the cells (Yang et al., 2014).  One 
limitation of iPSC-based approaches is that AMD might involve systemic defects that are not 
recapitulated in the culture of a single cell type.  More complex human tissue structures that 
better reproduce physiological conditions and disease characteristics are being developed for 
future research (Gamm et al. 2013).  By combining an RPE monolayer with other retinal 
cells, or with a modeled choroid capillary bed, investigators can study the interaction 
between cells that might contribute to disease.   
In the human eye, the blood–retinal barrier consists of three layers: the RPE 
monolayer, Bruch’s membrane, and the underlying choriocapillaris, a network of small blood 
vessels.  Recreating this native architecture should lead to more physiologically relevant 
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models (Lehr, 2005).  A functional barrier model was created with cultured RPE and human 
vascular cells separated by amniotic membrane (Hamilton and Leach, 2011).  Synthetic 
Bruch’s membranes constructed from fibroin, a silk protein, also support the co-cultivation of 
RPE cells and microvascular endothelial cells (Shadforth et al., 2012).  Such three-
dimensional cell-culture systems might be used to model the development of wet AMD by 
recreating disease-associated interactions among vascular cells, Bruch’s membrane, and RPE 
cells (Feigl and Hutmacher, 2013).  Stem cell-based three-dimensional models should also 
greatly accelerate AMD research and drug development (Pampaloni et al., 2007).     
 Future models and therapies also might take advantage of layered retinal tissues that 
spontaneously form in stem cell cultures (Westenskow et al., 2014).  A structure similar to 
the embryonic optic cup, which contains integrated RPE and neurosensory layers, can self-
organize in mouse and human stem cell cultures (Zhong et al., 2014; Eiraku and Sasai, 2012).  
If this process could be controlled, such engineered tissues might be used as a clinical-grade 
transplant to replace entire sections of damaged retina (Nakano et al., 2012).  In the following 
section, we further investigate the cellular transplantation strategies currently in development 
as potential AMD therapeutics.  
 
Cell-based therapeutics for AMD 
RPE cell transplantation is a promising clinical strategy for treating AMD (Carr et al., 2013; 
Rowland et al., 2013).  Both hESC-RPE and human iPSC-RPE are currently in clinical trials 
for AMD (Table 1.3, Cyranoski, 2014; Schwartz 2014).   
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Table 1.3. Stem cell-based AMD therapies in development. 
Therapy Developer Status (2015) 
Suspension hESC-RPE cells 
Suspension hESC-RPE cells 
hESC-RPE monolayer on support  
hESC-RPE monolayer on support 
iPSC-RPE monolayer, no support 
Adult autologous iPSC-RPE  
Suspension  neural stem cells 
Suspension umbilical cord stem cells 
Suspension bone marrow stem cells 
Ocata Therapeutics, U.S. 
CellCure Neurosciences, Israel 
London Project to Cure Blindness/Pfizer, U.K. 
California Project to Cure Blindness/CIRM, U.S. 
RIKEN Center for Developmental Biology 
Cellular Dynamics International/NEI, U.S. 
StemCells Inc., U.S. 
Janssen R&D, LLC, Belgium  
University of California Davis, U.S. 
Phase 2 
Phase 1/2  
Phase 1  
Phase 1 
Phase 1/2 
Pre-clinical 
Phase 2 
Phase 1 
Phase 1 
Abbreviations: CIRM = California Institute for Regenerative Medicine; hESC-RPE = human embryonic stem 
cell derived retinal pigmented epithelial cells; iPSC-RPE = induced pluripotent stem cell derived RPE, NEI = 
National Eye Institute (U.S.). The studies listed here are in or near clinical trials (Phase 3 treatments can be 
marketed upon approval by the U.S. Food and Drug Administration). Several other potential therapies for AMD 
are currently in the planning stage of development.  Sources: www.clinicaltrials.gov (U.S. National Institutes of 
Health); Bharti et al. (2014); Sheridan (2014).  
 
There are two strategies for cell transplantation: injection of a suspension of cells, and 
surgical implantation of an RPE monolayer, with or without a supporting membrane (Fig. 
1.2).  In the RCS rat, a classic animal model of retinal degeneration, injected hESC-RPE cell 
suspensions showed some incorporation into the native RPE layer and restored visual 
function (Lu et al., 2009).   
 Long-term studies of the injected cells showed no tumor formation over the lifetime 
of immune system-deficient mice.  Although the injection procedure is less invasive than 
monolayer implantation, injected RPE cells tend to form clusters and show limited 
phagocytosis of photoreceptor outer segments in rat models (Carr et al., 2009).  An 
experiment comparing injection and implantation of hESC-RPE revealed that implanted 
monolayers survived longer (up to 12 months) without evidence of tumor formation in 
immuno-compromised rats (Diniz et al., 2013). Initial results from the first human clinical 
trials using suspension injections of hESC-RPE indicated that patients showed no signs of 
tumor formation (Schwartz et al., 2012).  
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Fig. 1.2. An RPE cell implant. A patch of therapeutic RPE cells might treat those afflicted 
with age-related macular degeneration.  These hESC-RPE cells were grown on a parylene 
support (the implant body measures approximately 3.5 x 6 millimeters).  Image credits: Dr. 
Britney Pennington, UC Santa Barbara (above), University of Southern California (below).  
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A more recent follow-up study of the 18 patients also revealed no serious safety issues 
related to the injected cells (Schwartz et al., 2014).  While a trend towards improved vision 
was noted, the trial was designed to assess safety.  More extensive trials will be needed to 
determine meaningful efficacy.  A scaffold-free layer of iPSC-RPE, designed for clinical use, 
also showed no immune rejection or tumor formation when implanted in a primate model 
(Kamao et al., 2014).  Based on this research, a Japanese woman recently became the first 
AMD patient to ever receive a transplanted layer of autologous iPSC-RPE cells (Cyranoski, 
2014).  Patient-derived cells minimize the risk of immune rejection and might eventually be 
used for gene therapy.  In this case, the iPSCs would be altered to remove a risk-conferring 
gene variant.  The cells might then be differentiated into healthy RPE cells and transplanted 
into the retina (Selvaraj et al., 2010).  A proof-of-concept experiment demonstrated that 
disease-free blood cell progenitors could be created from patients with Fanconi anaemia 
(Raya et al., 2009).   
 Multipotent stem cells that reside within the adult retina, called RPE stem cells 
(RPESCs), might be another cell source for replacement therapy or disease modeling (Salero 
et al., 2012).  When exposed to chronic oxidative stress in culture these cells upregulate 
expression of several drusen-related proteins, demonstrating their use as a model for early 
AMD (Rabin et al., 2013).  Because adult RPESCs retain the ability to proliferate, they might 
be a source of therapeutic cells to repair damaged RPE monolayers (Coffey, 2012).  A 
polarized RPESC monolayer, grown on a biocompatible support membrane, retained RPE 
characteristics for over a month after sub-retinal implantation in a rabbit model of AMD 
(Stanzel et al., 2014).   
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 Future RPE implants might include biocompatible scaffolds that mimic a healthy 
Bruch's membrane (Liu et al., 2014).  For example, nanopatterned, porous poly(ε-
caprolactone) (PCL) films are biocompatible, allow for metabolite transport, and improve 
hfRPE cell function compared to non-porous PCL or porous polyester (McHugh et al., 2014).  
There are many other polymers and engineered materials with potential uses in RPE 
transplantation, including parylene (Croze and Clegg, 2014).   
 Parylene, a xylene-based hydrocarbon polymer that is already approved for 
biomedical use, can be engineered with ultrathin regions with permeability similar to that of 
Bruch’s membrane (Lu et al., 2012).  hESC-RPE cultured on these ultrathin parylene-C 
membranes are able to adhere, proliferate, develop polarized monolayers, and maintain RPE 
characteristics.  Innovative surgical techniques were developed to implant the parylene 
substrates into a rat model of AMD, where >98% of the transplanted RPE cells survived the 
procedure (Hu et al., 2012).   
 
Conclusions and future directions  
 There is now considerable basic research and private sector interest in producing RPE 
cells for transplantation.  Mass production of differentiated cells with the functional 
morphology and characteristic marker expression of RPE cells is now possible (Maruotti et 
al., 2013).   
However, potential immune responses and transplant rejection remains a significant 
challenge for cellular therapies.  Advanced methods to create genetically matched cell lines, 
such as somatic cell nuclear transfer, remain to be developed (Yabut and Bernstein, 2011).  
However, it is feasible to create and maintain banks of “super donor” hESC-RPE cell lines to 
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minimize transplant rejection and the need for immunosuppressive drugs (Lund, et al. 2006).  
It is also possible to create a bank of pluripotent cell lines to match the human leukocyte 
antigen “cell type” and minimize immune reactions for a large percentage of the population 
(Nakatsuji et al. 2008). 
 The optimal transplant strategy for long-term RPE survival and function remains to 
be determined (Kvanta and Grudzinska, 2014).  In addition, some questions remain regarding 
the safety and efficacy of differentiated cells derived from iPSCs (Kokkinaki et al., 2011). 
Recent studies show that iPSCs are prone to genetic and epigenetic abnormalities with a 
higher number of mutations, copy number variations (CNVs), and unusual DNA methylation 
patterns relative to hESCs (Pera, 2011).  DNA sequencing analysis of 20 human iPSC lines 
revealed that some of those variations were already present in the donor cells (Abyzov et al., 
2012).  In other words, there may be a background level of cellular “mosaicism” in donor 
tissues that can lead to cell line variability.  New analytical tools are being developed to 
provide genome-wide reference maps of DNA methylation and gene expression profiles for 
multiple stem cell lines.  For example, these tools were used to assess the epigenetic and 
transcriptional similarity of 32 different hESC and iPSC lines (Bock et al., 2011).  This might 
lead to a comprehensive method to characterize the genetic features of any stem cell line, and 
to predict their differentiation efficiencies. RPE cell-replacement therapies are of great 
potential and offer considerable hope for the treatment of AMD.  However, stem cell-based 
disease modeling and transplantation requires a long-term, multi-disciplinary approach.  This 
coordinated effort must integrate biomedical research and materials science, together with 
clinical application, commercial interest, and financing. Therefore, significant challenges, 
and opportunities, remain to fully develop these therapies.  
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Chapter II 
 
A Cell Culture Model that Mimics Drusen Formation and Triggers 
Complement Activation Associated with Age-related Macular 
Degeneration 
 
Abstract 
We introduce a human retinal pigmented epithelial (RPE) cell culture model that mimics 
several key aspects of early stage age-related macular degeneration (AMD). These include 
accumulation of sub-RPE deposits that contain molecular constituents of human drusen, and 
activation of complement leading to formation of deposit-associated terminal complement 
complexes. Abundant sub-RPE deposits that are rich in apolipoprotein E (APOE), a 
prominent drusen constituent, are formed by RPE cells grown on porous supports. Exposure 
to human serumresults in selective, deposit-associated accumulation of additional known 
drusen components, including vitronectin, clusterin, and serum amyloid P, thus suggesting 
that specific protein–protein interactions contribute to the accretion of plasma proteins during 
drusen formation. Serum exposure also leads to complement activation, as evidenced by the 
generation of C5b-9 immunoreactive terminal complement complexes in association with 
APOE-containing deposits. Ultrastructural analyses reveal two morphologically distinct 
forms of deposits: One consisting of membrane-bounded multivescicular material, and the 
other of nonmembrane-bounded particle conglomerates. Collectively, these results suggest 
that drusen formation involves the accumulation of sub-RPE material rich in APOE, a 
prominent biosynthetic product of the RPE, which interacts with a select group of drusen-
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associated plasma proteins. Activation of the complement cascade appears to be mediated via 
the classical pathway by the binding of C1q to ligands in APOE-rich deposits, triggering 
direct activation of complement by C1q, deposition of terminal complement complexes and 
inflammatory sequelae. This model system will facilitate the analysis of molecular and 
cellular aspects of AMD pathogenesis, and the testing of new therapeutic agents for its 
treatment. 
 
Introduction 
Age-related macular degeneration (AMD) is characterized in its early stages by the presence 
of extracellular deposits, known as drusen, that accumulate between the basal surface of the 
retinal pigmented epithelium (RPE) and Bruch’s membrane, an extracellular matrix complex 
that separates the neural retina from the capillary network in the choroid. Early electron 
microscopic studies suggested that drusen formation may be a consequence of degeneration 
of the RPE (1–3), initiated by membranous debris shed from its basal surface (4, 5). These 
early morphological observations have since been confirmed by a number of more recent 
studies (6–13).  
 Contemporary investigations of the molecular composition of drusen have provided 
additional insights into their biogenesis. Immunohistochemical and proteomic studies show 
that drusen contain a variety of protein and lipid components (14, 15). Among these are 
several plasma proteins, the presence of which implies a systemic contribution to their 
genesis. Although the primary biosynthetic source for most of these circulating molecules is 
the liver, a number of them are also known to be synthesized locally by RPE cells (15–19). 
The respective contributions of RPE-derived and plasma-derived molecules to the process of 
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drusen biogenesis, as well as the relevant molecular interactions leading to drusen deposition, 
have not yet been fully elucidated.   
 During the past decade, compelling evidence has emerged implicating the immune 
system—and the complement system in particular—in drusen biogenesis and AMD (15, 20, 
21). A number of the proteins detected in drusen are either complement components or 
related molecules. Importantly, variations in several complement-related genes have been 
shown to be highly significant risk factors for the development of AMD (20, 21). Taken 
together, these findings are consistent with the general conclusion that chronic local 
inflammation at the RPE/Bruch’s membrane interface contributes to drusen formation and to 
AMD pathogenesis (12, 14, 22, 23).  
 Despite these significant advances, the identity of the molecules responsible for 
triggering activation of the complement cascade, as well as the downstream molecular 
interactions that promote AMD pathology, remain elusive. This is due, in part, to the dearth 
of animal and cell culture models that reproduce the most salient pathologic features of AMD 
under controlled experimental conditions. We introduce here an RPE cell culture model that 
mimics numerous aspects of AMD pathology observed in humans, including accumulation of 
sub-RPE deposits containing known constituents of drusen, activation of the complement 
system, and deposition of terminal complement complexes. This system provides a unique 
experimental platform that will facilitate dissection of the cellular and molecular events that 
lead to drusen formation and contribute to AMD pathogenesis. 
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Results 
Examination of differentiated cultures of primary human RPE cells grown on porous 
supports led to the identification of a population of globular extracellular deposits that 
accumulate within the pores of the support material. Initially, we identified these sub-RPE 
deposits based on their immunoreactivity for apolipoprotein E (APOE) (Fig. 1). Antibodies 
to several other apolipoproteins, including apolipoproteins A and B, did not show similar 
immunoreactivity. APOE is a circulating lipid transport protein, a ubiquitous component of 
human ocular drusen (24–26), and an abundant biosynthetic product of RPE cells (16, 24). 
The APOE deposits are typically spheroid, sometimes tubular in shape, ranging from 0.5 to 3 
μm in diameter. They accumulate within the porous culturematrix and aremost concentrated 
within 20 μmof the basal surface of the RPE. The deposits are non-uniformly distributed 
along the substratum, with areas of higher density interspersed with areas where the deposits 
are relatively sparse (Fig. 1).  
This sporadic distribution of sub-RPE material is consistent with the irregular pattern of 
drusen development in the eye. The accumulation of APOE from bovine serum that is a 
constituent of the RPE cell culture medium does not appear to contribute to the APOE 
immunoreactivity because cell culture inserts without cells incubated in bovine serum-
containing medium and assayed immunocytochemically for APOE show no evidence of 
immunoreactivity (Fig. S1).  
 The APOE-containing deposits also show comparatively low levels of 
immunoreactivity for two other known drusen constituents, clusterin (17, 18, 22) and 
vitronectin (7, 27), that have been reported to be biosynthetic products of the RPE. However, 
following exposure to human serum, immunoreactivity for both clusterin and vitronectin is 
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apparent within these deposits (Fig. 2). Serum exposure also facilitates the accumulation of a 
third plasma protein and known drusen constituent, serum amyloid P component (APCS) 
(28). Both vitronectin and APCS are also detected in a few deposits with minimal or no 
APOE immunoreactivity (Fig. 2). In contrast, haptoglobin, another highly abundant plasma 
protein, but one that is not typically found in drusen, is not detected (Fig. S2), suggesting that 
there is a selective accumulation of plasma-derived proteins in sub-RPE deposits. The 
presence of both RPE- and plasma-derived proteins in these sub-RPE deposits is consistent 
with the compositional profile of human drusen.  
 Strikingly, exposure of the cultures to human serum also enables activation of the 
complement system, as demonstrated by the deposition of C5b-9 terminal complement 
complexes in association with the sub-RPE deposits. Anti–C5b-9 immunoreactivity is 
associated with particulate material that often codistributes with APOE-containing deposits 
(Fig. 3), but the APOE and C5b-9 immunoreactivity patterns are not strictly colocalized, 
indicating that they represent spatially distinct elements of the deposits. Notably, C5b-9 
immunoreactivity is associated only with the basal deposits, and not with the surfaces of 
viable RPE cells. Consistent with this observation, these deposits are not typically labeled 
with an antibody directed against Glycoprotein NMB (GPNMB), an abundant RPE surface 
protein (29) (Fig. 1A). Cell-culture inserts without cells incubated in bovine serum-
containing medium and assayed immunocytochemically for C5b-9 show no evidence of 
immunoreactivity (Fig. S1), indicating that neither components of the medium nor the 
support matrix are responsible for complement activation and deposition of C5b-9 
complexes.  
31 
 
 By electron microscopy, two morphologically distinct deposit subtypes are identified: 
nonmembrane-bounded conglomerates of small osmophilic particles, and membrane-
bounded, multivesicular structures (Fig. 3). These two subtypes are sometimes segregated, 
and sometimes comingled within deposits.  
 We assessed the relative contributions of the different complement activation 
pathways to deposit-associated formation of C5b-9 terminal complement complexes by 
exposing cultures to human sera depleted of specific components required for activation of 
the classical or alternative pathways (Fig. 4 A–F). Initially, we confirmed that C5b-9 
immunoreactivity is abolished in the presence of serum depleted of C5, a required element of 
the terminal complement pathway. When cultures are exposed to serum depleted of Factor B, 
a component required for activation of the alternative pathway, no significant alteration in 
C5b-9 labeling levels is detected compared with whole serum controls. In contrast, when 
cultures are exposed to serum depleted of C1q, a component required for formation of the C1 
complex and activation of the classical pathway, C5b-9 immunoreactivity associated with 
sub-RPE deposits is dramatically reduced. Replenishment of the depleted serum with purified 
C1q restores C5b-9 immunoreactivity. The presence of C1q in association with APOE-
containing deposits following serum exposure was confirmed immunocytochemically (Fig. 4 
H–I), indicating that molecular components of these deposits have both C1q-binding and 
complement-activating properties. Exposure of cells to human serum previously treated with 
cobra venom factor, in order to irreversibly activate the C3 convertase and generate abundant 
soluble C5b-9 complexes (30), results in markedly reduced levels of C5b-9 immunoreactivity 
(Fig. S3). This finding indicates that the association of preformed, soluble C5b-9 complexes 
with sub-RPE deposit material does not contribute significantly to deposit-associated C5b-9 
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immunoreactivity. Classical pathway activation is most often triggered by binding of C1q to 
antigenantibody complexes. Therefore, we also assessed the ability of human serum depleted 
in IgG to provoke C5b-9 formation. IgG depletion has no detectable effect on deposit-
associated C5b-9 immunoreactivity levels compared with whole serum controls (Fig. S4), 
thus suggesting that activation of the classical pathway occurs via an antibody-independent 
mechanism. 
 
Discussion 
In this study, we introduce an RPE cell-culture model system that mimics facets of drusen 
formation and complement activation in vivo. Highly differentiated human RPE cells grown 
on a permeable support produce extracellular sub-RPE deposits that accumulate within the 
pores of the supporting material over the course of several weeks in culture. 
Immunocytochemical analyses show that these sub-RPE deposits contain some of the most 
abundant protein constituents of human drusen. One of these, APOE, is a ubiquitous drusen 
associated protein that is synthesized and secreted by the RPE (24). Others, including 
vitronectin, clusterin, and APCS, selectively accumulate in APOEcontaining deposits when 
exposed to human serum. Haptoglobin, another abundant plasma protein, does not show 
similar accumulation. Taken together, these findings suggest that specific protein–protein 
interactions between RPE-derived and plasma-derived proteins are involved in the formation 
of these in vitro deposits, just as they appear to be in the process of drusen biogenesis in vivo. 
 Another population of sub-RPE deposits formed in vitro are the target of complement 
activation and formation of the terminal complement complex [i.e., the membrane attack 
complex (MAC): a cytolytic, macromolecular complex consisting of the C5b fragment, C6, 
33 
 
C7, C8, and multiple C9 molecules (C5b-9n)].When cultures are incubated with human 
serum, a complete source of complement system components, C5b-9 immunoreactivity is 
detected in association with particulate deposits that are distinct from, but in close proximity 
to, the more globular APOE-containing deposits. C5b-9 immunoreactivity is not detected on 
intact RPE cell membranes, most likely because of the robust expression of membrane 
associated complement inhibitors by the RPE (15, 31, 32).  
 The substructural morphology of the in vitro deposits (Fig. 3B) is consistent with the 
fine structure of sub-RPE deposits identified in vivo. The membrane-bounded form has 
similarities to the RPE derived, membranous blebs described originally by both Burns and 
Feeny-Burns (4) and Ishibashi et al. (5) in human tissue sections. This form would appear to 
be the most likely site of deposit-associated MAC deposition and C5b-9 immunolabeling, 
since formation of the MAC requires membrane insertion. On the other hand, the 
particles/vesicles within the enclosing membrane have dimensions similar to the lipoprotein 
particles previously described as components of drusen and other sub-RPE deposits (9, 26, 
33–38). At this point, we have not determined whether APOE immunoreactivity is associated 
with one or both substructural forms of sub-RPE deposits, and we did not attempt to identify 
the lipid moieties associated with APOE. Further analyses using protocols designed for 
enhanced preservation of lipids will be required to more accurately characterize the nature of 
lipid materials associated with the sub-RPE deposits and expanded, unbiased proteomic 
profiling will be required to reveal the entire spectrum of proteins comprising the deposits. 
 RPE cells express transcripts for APOE at levels comparable to those in the liver and 
brain, the two most abundant biosynthetic sources of APOE (24). APOE is secreted in 
considerable amounts by RPE cells both apically and basally, and has been implicated in 
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lipid trafficking, facilitating the efflux of lipids from the RPE, and their transit across Bruch’s 
membrane to the choroidal vasculature (16). In human RPE/choroid tissue, we previously 
documented the presence of APOE-immunoreactive structures of similar size and 
morphology to those we observe in vitro (24), thus suggesting that the basal shedding of 
APOEcontaining material also occurs in situ. Drusen-associated immunoreactivity for 
apolipoproteins A-1 and B has been shown in other studies (37, 38); however, we did not 
observe immunoreactivity for these moieties in the deposits. These results may be related to 
antibody-dependent issues and/or the nature of the cell culture system employed.  
 Although AMD risk-conferring gene polymorphisms have been identified for 
complement Factor H, the major negative regulator of the alternative complement pathway, 
the alternative pathway does not appear to be the primary activation pathway in this system. 
Serum depletion of Factor B, a complement component required for alternative pathway 
activation, does not diminish deposition of C5b-9 complexes. However, when cultures are 
incubated in serum depleted of C1q, a pattern-recognition molecule required for classical 
pathway activation, C5b-9 immunoreactivity levels are dramatically reduced. 
Supplementation with purified C1q restores C5b-9 immunoreactivity. These findings 
implicate the classical pathway as the principal activation pathway, and suggest that it may 
be mediated directly via C1q binding. Because the alternative pathway acts as an 
amplification loop for the classical pathway and can be stimulated by classical pathway 
activation (39), this conclusion is not inconsistent with a role for the alternative pathway in 
AMD. Given this interplay between the classical and alternative pathways, some diminution 
of C5b-9 deposition might have been expected in the absence of Factor B. However, high 
concentrations of complement Factor H in the human serum may act to effectively repress 
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the alternative pathway in this in vitro system. In vivo, where local Factor H concentrations 
are likely lower, dysregulation of the amplification loop of the alternative pathway stemming 
from Factor H dysfunction would be predicted to exacerbate complement-mediated 
inflammation with pathologic consequences (40).  
 The classical pathway is typically triggered by binding of C1q to the Fc fragment of 
IgG or IgM in clusters of antigen-antibody complexes on the surfaces of microbial 
pathogens. When exposed to serum depleted of IgG, C5b-9 immunoreactivity levels are 
unaffected, thus suggesting that activation is not triggered by an antibody-mediated 
mechanism. However, the classical pathway can also be activated by direct binding of C1q to 
a variety of other molecules, such as C-reactive protein, APCS, amyloid-β, and modified 
LDL cholesterol (41, 42). In addition, C1q can bind apoptotic cells and cell membrane blebs 
with consequent activation of the classical complement pathway (43–45). Collectively, these 
findings are consistent with the general conclusion that one or more C1q-binding molecules 
are the most likely triggers of the complement cascade in this system and perhaps in the eye 
as well. The identification of C1q in association with APOE-containing deposits following 
serum exposure suggests that they contain a molecular ligand for C1q, and thus a potential 
activator of the complement cascade. Membranous deposits that lie in close proximity to the 
APOE/C1q-containing deposits would then be predicted to provide the surface required for 
MAC formation. Further analyses will be required to identify specific C1q binding partners 
that may be responsible.  
 Previous studies of sub-RPE deposit formation in vitro used ARPE-19 cells grown on 
impermeable tissue-culture plastic. Under these conditions, sub-RPE deposits with drusen-
like properties were not apparent, nor were known drusen constituents identified (46, 47). 
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Interestingly, Amin et al. (46) did note an increase in total membranous and condensed 
deposits when cells were cultured on porous supports as opposed to tissue-culture plastic. In 
the in vitro system we describe here, the macromolecular material shed at the basal RPE 
surface tends to accumulate in the pores of the culture support. The size and shape of the 
deposits are likely to be influenced by the physical dimensions of the substrate pores and, to 
some extent, this porous meshwork may also act to retain deposit material, limiting its 
diffusion into the basal medium compartment.  
 In situ, it is probable that a mechanism exists for the removal of basally shed RPE 
debris because, early in life, it does not typically accumulate in the sub-RPE compartment. 
However, disruption of the normal clearance mechanism, perhaps as a result of age-related 
changes in phagocytic activity, immune function, and/or the structure and composition of 
Bruch’s membrane, would be predicted to lead to the accumulation of sub-RPE debris and 
eventually to the formation of human drusen. If this model is correct, the use of experimental 
substrates with biochemical and diffusional properties that mimic the lipid-rich, hydrophobic 
environment that characterizes the aged Bruch’s membrane might result in the buildup of 
deposit aggregates that more closely resemble human drusen. Alternatively, interactions 
among drusen-associated proteins and lipids that are not present in our in vitro system may 
be required for the establishment of characteristic drusen morphology.  
 It is noteworthy that complement-activating sub-RPE debris is formed by cultured 
human RPE cells that are not exposed to shed photoreceptor outer segments and, thus, are not 
impacted by the metabolic derivatives of membrane lipids that have been proposed as 
complement-activating and immunogenic elements in AMD (48, 49). However, such factors, 
in conjunction with aging, environmental influences, and genetic predisposition could play a 
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role in promoting the susceptibility of RPE cells to directed or bystander complement attack 
in vivo. We do not find evidence for RPE-directed complement attack (i.e., C5b-9 complexes 
associated with the RPE cell surface), most likely because the cells are chronologically 
young (derived from fetal sources), express membrane-associated negative regulators of 
complement including CD46, CD55, and CD59 (15, 31, 32), and have not been affected by 
senescence or exposed to environmental “stressors.”  
 Importantly, the cell-based system we have used in these studies recapitulates some 
of the key pathologic processes at play in AMD. As such, this system should facilitate 
rigorous experimental analysis of the molecular basis of drusen formation and complement 
activation in AMD, the evaluation of known AMD risk factors at cellular and molecular 
levels, and the testing of novel therapeutic strategies for the treatment of AMD in its earliest 
stages. 
 
Methods 
RPE Cell Culture. RPE cells were derived from human fetal eyes (Advanced Bioscience 
Resources) as described by Hu and Bok (50). Early passage (p1–p2) cells were seeded onto 
laminin-coated porous supports (Millipore Millicell- HA Culture Plate Inserts, PIHA 01250) 
and cultured in “Miller medium” (51). One- to 3-mo postseeding, cultures were exposed to 
complement-competent human sera, human sera depleted of C1q, C5, or Factor B (Table S1), 
or human serum depleted of IgG by absorption with protein A/G coupled to agarose beads 
(Pierce) (Fig. S4) at 10% (vol/vol) in serum-free Miller medium for 24 h. The specimens 
were then rinsed in PBS (3×, 15 min), fixed for 10 min in 4% paraformaldehyde in PBS, and 
stored in 0.4% paraformaldehyde pending sectioning and immunohistochemical analyses.  
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Immunohistochemistry. Confocal laser scanning immunofluorescence imaging was 
performed as described previously (52) on 100-μm vibratome sections or flat mounts of fixed 
RPE cell cultures. Flat mounts were bleached (Melanin Bleach Kit; Polysciences) for 10 min 
to allow visualization of sub-RPE deposits that would otherwise be obscured by RPE 
pigment. Antibodies utilized are listed in Table S2. 
Electron Microscopy. RPE cultures were fixed in 2% glutaraldehyde and 2% formaldehyde, 
postfixed in 2% osmium tetroxide, dehydrated in a graded ethanol series up to 100% and 
embedded in LX-112 resin (Ladd Research). Thin sections were stained with 2% uranyl 
acetate and lead citrate and imaged on a JEOL JEM-1230 transmission electron microscope. 
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Figures: 
 
 
 
Fig. 2.1. APOE-containing basal deposits are elaborated by human RPE cells in vitro. 
Confocal immunofluorescence images of sectioned (A and B) and flatmounted (C) RPE cell 
cultures on porous supports. Spherical to amorphous deposits that are immunoreactive for 
APOE (green, arrows) accumulate within the support matrix. These deposits are 
nonuniformly distributed with areas of high deposit density (arrows in A and C) interspersed 
among areas with few to no detectable deposits (asterisk in A). Immunoreactivity for 
GPNMB (red in A), an abundant RPE membrane protein, is localized to RPE cell surfaces 
and to particulate sub RPE material (arrowheads in A) that is distinct from the APOE 
deposits. Blue, nuclear (“N” in B) DAPI fluorescence in A and B. (Scale bars, 10 μm in A 
and C; 5 μm in B.) 
 
 
 
 
Fig. 2.2. (Following page) Association of serum proteins with APOE deposits. Double-label 
confocal immunofluorescence images showing localization of APOE (red) and vitronectin 
(green inA-F), clusterin (green inG–L), or serumamyloid P component (APCS, green inM–R) 
in sub RPE depositswith orwithout exposure to human serum (±SERUM). RPE nuclei are 
indicated by blue DAPI fluorescence. Deposit-associated APOE immunoreactivity is present 
without human serum exposure (A, G, M); comparatively weak immunoreactivity is detected 
for vitronectin (B) and clusterin (H), but not for APCS (N). Following exposure to 10% 
human serum for 24 h, APOE immunoreactivity associatedwith sub-RPE deposits 
ismarginally increased (C, I,O),whereas there is substantially increased deposit-associated 
immunoreactivity for vitronectin (D), clusterin (J), and APCS (P). Merged images (E, F, K, 
L, Q, R) show striking overlap of immunoreactivity (yellow), indicating that serum 
vitronectin, clusterin, and APCS, all known drusen constituents, selectively associate with 
APOE-containing sub-RPE deposits. Almost all APOE deposits show evidence of 
colocalization with these serum proteins; however, there are examples where there is 
minimal colocalization of vitronectin (arrowhead in F) and some where APCS 
immunoreactivity appears to be largely independent of APOE (arrowhead in R). (Scale bars, 
10 μm in A, applicable to A–E, G–K, and M–Q; 3.5 μm in F, applicable also to L and R.) 
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Fig. 2.3. Complement activation by sub-RPE deposits/ultrastructure. (A) Confocal image 
showing APOE immunofluorescence (green) associated with spheroid to globular sub-RPE 
deposits and C5b-9 immunofluorescence (red) associated with particulate deposit material 
that is frequently apposed to the surfaces of the APOE deposits (arrows). Blue, nuclear DAPI 
fluorescence. (B) Electron microscopic image illustrating the membrane-bounded, 
multivesicular (arrow) and dense, aggregated (arrowhead) forms of sub-RPE deposits 
identified ultrastructurally. The deposits occupy anastomotic space among processes that 
make up the support matrix (M). (Scale bars, 10 μm in A, 400 nm in B.) 
 
Fig. 2.4. Deposit-associated complement activation is C1q-dependent. Immunoreactivity for 
deposit-associated terminal complement complexes (C5b-9 neoepitope, red in A–G). In the 
absence of human serum exposure, C5b-9 immunoreactivity (A) is indistinguishable from the 
secondary antibody control (B), confirming the serum-dependence of C5b-9 formation. 
Abundant C5b-9 immunoreactivity is detected following exposure to complete human serum 
(C), but only background levels of fluorescence are detected following exposure to sera 
depleted of C5 (D), or C1q (F). The markedly reduced C5b-9 immunoreactivity in the 
presence of C1q-depleted serum (F) implicates classical pathway activation, whereas the 
presence of C5b-9 immunoreactivity on exposure to Factor B depleted serum (E), at levels 
similar to that of whole serum (C), indicates a lack of significant contribution by alternative 
pathway activation. Restoration of complement activation by reintroduction of C1q into C1q 
depleted serum (G) confirms dependence on C1q for deposit-associated complement 
activation. Immunoreactivity for C1q (red in I and J) and APOE (green in H and J) colocalize 
in many APOE-containing sub-RPE deposits following serum exposure (arrowheads in J). 
C1q also is associated with basal regions of RPE cells (asterisks in I and J). Blue, nuclear 
DAPI fluorescence. (Scale bars, 10 μm in A and applicable to A–G; 10 μm in H and 
applicable to H–J.) 
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Fig. 2.5. (Figure S1). Anti-apolipoprotein E (APOE) (green in A) and anti-C5b9 (red in B) 
immunostaining of a cell culture membrane without cells following exposure to retinal 
pigmented epithelial (RPE) culture medium containing 5% FBS for 7 d at 37 °C. There is no 
evidence of deposit-like APOE or C5b-9 immunoreactivity, indicating that the APOE 
immunoreactivity observed in association with sub-RPE deposits is not related to deposition 
of bovine APOE from the medium, and that C5b-9 immunoreactivity is not the result of 
complement activation by other components of the medium or the matrix material. A 
secondary antibody control image is shown in C. 
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Fig. 2.6. (Figure S2). Deposit-associated haptoglobin immunoreactivity (green) is not 
detected following exposure to human serum indicating there is selective association of 
serum proteins with APOE-containing sub-RPE deposits. Blue, nuclear DAPI fluorescence. 
 
 
 
 
 
49 
 
 
Fig. 2.7. (Figure S3). Confocal immunofluorescence images showing C5b-9 
immunoreactivity (red) following exposure of RPE cultures to human serum pretreated for 24 
h with cobra venom factor (A) or untreated control serum (B). Cobra venom factor forms a 
C3 convertase with Factors B and D that is not inhibited by Factor H; it exhausts the 
complement system by cleavage of essentially all C3 and C5 resulting in the generation of 
high levels of soluble C5b-9 complexes. The lack of deposit-associated C5b-9 
immunoreactivity (exemplified by red in B) following exposure to cobra venom factor-
treated serum (A) demonstrates that it is not the result of binding of preformed soluble C5b-9 
complexes to the deposits. Blue, nuclear DAPI fluorescence. 
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Fig. 2.8. (Figure S4). Depletion of IgG from human serum does not affect deposit-associated 
C5b-9 immunoreactivity. (A) Anti-human IgG heavy chain immunoblot analysis of human 
serum samples before (lane 1) or after single (lanes 2 and 4) or double (lanes 3 and 5) 
absorption with unconjugated agarose beads (lanes 2 and 3) or Protein A/G-conjugated 
agarose beads (lanes 4 and 5). Numbers indicate band density expressed as percentage of the 
untreated control serum (lane 1). Double absorption with Protein A/G removes >96% of IgG 
(lane 5). (B and C) Confocal immunofluorescence images showing that sub-RPE deposit-
associated C5b-9 immunoreactivity (red) is not diminished when cultures are exposed to 
IgG-depleted serum (B, serum shown in lane 5 of A) compared with agarose-treated control 
serum (C, serum shown in lane 3 of A). 
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Tables: 
Table S1. Human sera 
Serum ID Source Catalog # 
Single-donor complement-competent sera 
     Lot D10839 
     Lot L12402 
     Lot J81977 
Depleted sera 
     C1q-depleted 
     C5-depleted 
     Factor B-depleted 
 
Innovative Research 
Innovative Research 
Innovative Research 
 
Complement Technology 
Complement Technology 
Complement Technology 
 
IPLA-CSER 
IPLA-CSER 
IPLA-CSER 
 
A300 
A320 
A335 
 
 
Table S2. Antibodies 
Antigen Host species/type Source Catalog # Lot # Dilution  
APOA 
APOB 
APOE 
C1q 
C5b-9 
Clusterin 
GPNMB 
APCS  
Vitronectin 
Goat/polyclonal 
Goat/polyclonal 
Goat/polyclonal 
Chicken/polyclonal 
Mouse/monoclonal 
Goat/polyclonal 
Mouse/monoclonal 
Rabbit/polyclonal 
Rabbit/polyclonal 
ThermoScientific 
ANAWA 
Millipore 
Abcam 
Dako 
Chemicon 
R&D Systems 
Dako 
Chemicon 
PA1-22558 
0650-0804 
AB947 
Ab14004 
MO777 
AB825 
MAB25501 
A0302 
AB19014 
LL137046 
A951017 
NMM1762655 
606520 
00058918 
23050831 
WLZ01 
118 
0611044545 
1/100 
1/200 
1/1,000 
1/100 
1/200 
1/200 
1/500 
1/200 
1/1,000 
APSC, serum amyloid P component, APOA, apolipoprotein A, APOB, apolipoprotein B, APOE 
apolipoprotein E, GPNMB, glycoprotein NMB 
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Chapter III 
 
Novel Compstatin Family Peptides Inhibit Complement Activation by 
Drusen-like Deposits in Human Retinal Pigmented Epithelial Cell Cultures 
 
Abstract 
We have used a novel human retinal pigmented epithelial (RPE) cell-based model that 
mimics drusen biogenesis and the pathobiology of age-related macular degeneration to 
evaluate the efficacy of newly designed peptide inhibitors of the complement system. The 
peptides belong to the compstatin family and, compared to existing compstatin analogs, have 
been optimized to promote binding to their target, complement protein C3, and to enhance 
solubility by improving their polarity/hydrophobicity ratios. Based on analysis of molecular 
dynamics simulation data of peptide C3 complexes, novel binding features were designed by 
introducing intermolecular salt bridge-forming arginines at the N-terminus and at position -1 
of N-terminal dipeptide extensions. Our study demonstrates that the RPE cell assay has 
discriminatory capability for measuring the efficacy and potency of inhibitory peptides in a 
macular disease environment. 
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Introduction 
Drusen are extracellular deposits that are a hallmark of age-related macular degeneration 
(AMD) and a risk factor for advanced AMD pathology (CAPT, 2008; Klein et al., 2008; 
Rudolf et al., 2008). These deposits form between the basal surface of the retinal pigmented 
epithelium (RPE) and Bruch’s membrane and have been linked to the activation of the 
complement system and associated inflammatory processes that contribute to AMD 
pathogenesis (Hageman et al., 2001; Anderson et al., 2010). Immunohistochemical and 
proteomic studies have revealed that drusen contain numerous protein and lipid constituents 
that are likely to be derived via RPE biosynthesis and also by accretion of plasma 
components. 
 We recently developed a cell culture model that mimics several aspects of drusen 
biogenesis including the formation of sub-RPE deposits containing known drusen 
constituents, and deposit mediated complement system activation (Johnson et al., 2011). The 
sub-RPE deposits are rich in Apolipoprotein E (ApoE), a lipid transport protein which is a 
ubiquitous component of human ocular drusen (Anderson et al., 2001). Exposure of the RPE 
cells to human serum triggers formation of C5b-9 immunoreactive terminal complement 
complexes that are associated with the ApoE deposits (Johnson et al., 2011). Compounds 
with the ability to inhibit complement activation are potential therapeutics for AMD. 
Therefore, we employed this model system to test the effects of compstatin family peptides 
on sub-RPE deposit mediated complement activation. Compstatin family peptides are 
complement system inhibitors with sequence modifications that have been optimized over 
several years to improve anti-complement potency (reviewed in Morikis and Lambris (2005), 
Ricklin and Lambris (2007), 2008, Qu et al. (2009)). One compstatin peptide has been 
54 
 
evaluated in clinical trials as a therapeutic for AMD (clinicaltrials.gov, Identifier numbers: 
NCT00473928 and NCT01157065) (Ricklin and Lambris, 2007, 2008; Chi et al., 2010; 
Zarbin and Rosenfeld, 2010; Yehoshua et al., 2011; Qu et al., 2013). Compstatin inhibits the 
activation of the complement system, by binding to C3, the converging protein of all three 
complement activation pathways, and inhibiting the cleavage of C3 to C3a and C3b by C3 
convertase complexes. The mechanism of inhibition may be steric, by directly blocking 
convertase access to C3 or by blocking access of the convertase catalytic site to the C3 
scissile bond, and may involve conformational changes (Janssen et al., 2007; Ricklin and 
Lambris, 2008). The mechanism of binding between compstatin peptides and their target 
complement protein C3 is dominated by hydrophobic interactions, as well as hydrogen bonds 
(Janssen et al., 2007; Tamamis et al., 2012). Compstatin family peptides are typically 13- 
amino acids long, and cyclization by a disulfide bridge between the second and twelfth 
cysteine is necessary for activity (Sahu et al., 1996; Morikis et al., 1998, 2002; Sahu et al., 
2000). Seven of the 13 amino acids of compstatin family peptides have been shown to be 
indispensable for inhibitory activity in earlier studies (Morikis and Lambris, 2002; Morikis et 
al., 2002, 2004; Morikis and Lambris, 2005). A major breakthrough in the development of 
the most potent compstatin peptideswas the incorporation of aromatic amino acids, tyrosine 
and tryptophan, at position 4 of the sequence (Klepeis et al., 2003, 2004; Mallik et al., 2005), 
and subsequently methylation of the tryptophan at position 4 (Katragadda et al., 2006). 
Although these improvements resulted in a peptide with increased binding affinity and 
inhibitory activity (Magotti et al., 2009), the efficacy of this peptide is compromised by its 
propensity to precipitate in aqueous solutions. We attribute this self aggregation to the 
incorporation of a methylated tryptophan at position 4, which, together with a second 
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tryptophan at position 7 and a hydrophobic cluster at the linked termini (positions 1-4, 12, 
13), increases the overall hydrophobic character of the peptide, and decreases its aqueous 
solubility. We recently performed computational and rational design studies of compstatin 
peptides that showed that addition of tryptophan residues at the termini (sequence positions 1 
and 13) results in potent inhibiting peptides, evidenced by surface plasmon resonance and 
ELISA studies (Bellows et al., 2010a; López de Victoria et al., 2011), but aggregation issues 
were present even in the absence of methylation at position 4. We also performed multi-
trajectory molecular dynamics (MD) simulations to identify the binding properties of several 
of the newly designed peptides at atomic resolution and with the inclusion of conformational 
sampling (Tamamis et al., 2012). These studies not only revealed key 
structural/physicochemical and geometric elements of the peptide C3 binding cavity, but also 
suggested that a di-serine N-terminal extension and arginine replacement at the N-terminus 
produce additional contacts that improve the stability of the complex. Leveraging data from 
our recent (Bellows et al., 2010a; Tamamis et al., 2010; López de Victoria et al., 2011; 
Tamamis et al., 2012) and other studies of compstatin family peptides (Sahu et al., 1996; 
Morikis et al., 1998; Furlong et al., 2000; Sahu et al., 2000; Morikis and Lambris, 2002; 
Morikis et al., 2002; Klepeis et al., 2003; Soulika et al., 2003; Klepeis et al., 2004; Morikis et 
al., 2004; Mallik et al., 2005; Morikis et al., 2005; Morikis and Lambris, 2005; Katragadda et 
al., 2006; Janssen et al., 2007; Ricklin and Lambris, 2008; Magotti et al., 2009; Qu et al., 
2009), including MD simulation studies based on the structure of free (Mallik et al., 2003, 
2005; Mallik and Morikis, 2005; Song et al., 2005; Tamamis et al., 2007) and C3c-bound 
compstatin (Tamamis et al., 2010, 2011, 2012), we furthered the optimization of compstatin 
analogs using MD simulations. Our goal in this work is to increase the 
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polarity/hydrophobicity ratio in the peptide sequence without compromising the essential 
hydrophobic contacts with C3. Given the limited space for sequence optimization of the 
already highly optimized 13-amino acid compstatin peptides, and taking into account the new 
binding features of the N-terminal arginine and N-terminal dipeptide extension, we reasoned 
that introduction of polar amino acids at positions 1, 0, and -1 would achieve our goal to 
increase solubility and, therefore, reduce or eliminate aggregation. We present herein the 
screening results for complement inhibition of selected promising peptides using complement 
ELISAs and hemolytic assays. In addition, these peptides were screened in the 
aforementioned human RPE cell-based assay that approximates the disease characteristics of 
AMD. Given that compstatin is known to exhibit species specificity, and is not active in non-
primate species (Sahu et al., 2003; Tamamis et al., 2010), the RPE cell-based assay is 
advantageous as an initial screen for efficacy of the designed peptides in a human, ocular-like 
microenvironment, prior to advancing to experiments with primates and clinical testing. 
Additionally, we tested the peptide lipophilicities using reversed phase high performance 
liquid chromatography (RP-HPLC), as a measure of relative peptide hydrophobicity. Finally, 
we present molecular insights on the interactions between the N-terminal 
replacements/extensions and C3, based on the results of the MD simulations. 
 
Materials and Methods 
 
2.1. Peptide synthesis 
Compstatin family peptides were custom synthesized and characterized using liquid 
chromatography – mass spectrometry by Abgent Inc. (San Diego, CA, USA). The parent 
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compstatin peptide (control) was purchased either from Abgent (for C3b, C5b-9 ELISAs and 
hemolytic assay) or from TOCRIS Bioscience (Bristol, UK; for RPE cell-based assay). The 
peptides were acetylated at the N-terminus and amidated at the C-terminus, with the 
exception of parent compstatin control, whichwas not acetylated at the N-terminus. All 
peptides were cyclized through a disulfide bridge between Cys2 and Cys12. Peptides 
containing methylated tryptophan (methylated-Trp) were synthesized using Fmoc-1-methyl 
DL-tryptophan, and the resulting mixture of peptides containing D-methylated-Trp and L-
methylated-Trp were subsequently purified to obtain peptides containing only the L 
enantiomer. Additional characterization of the peptides was performed using HPLC and 
NMR (see below). The peptide sequences are shown in Table 1. Note, that the Roman 
numeral naming scheme of the peptides is different from that of our previous publication 
(López de Victoria et al., 2011). 
 
2.2. C3b and C5b-9 ELISAs 
Inhibition of the complement alternative pathway (AP) by compstatin family peptides was 
assayed by ELISA. Peptides were dissolved in phosphate buffered saline (PBS, 150 mM). 
Initial peptide concentrations were calculated using the Beer – Lambert Law with an 
extinction coefficient of 5500 (1/M cm) for Trp and 5470 (1/M cm) for methylated-Trp 
(Marmorstein et al., 1987) present in the sequence, at 280 nm. Nunc Maxisorp 96-well plates 
were coated with 1 mg lipopolysaccharides (LPS) from Salmonella enteritidis for ~16 h at 
room temperature. Plates were washed three times with PBS/0.05% Tween-20 (PBS-T) 
between each step. Plates were blocked with 4% bovine serum albumin (BSA) in PBS-T for 
1 h at 37° C. Serial peptide dilutions were performed in 96-well plates, using gelatin veronal 
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buffered saline with 5 mM MgCl2 and 10 mM EGTA (GVBS-MgEGTA). Normal human 
serum (Complement Technology Inc., Tyler, TX, USA) was diluted in GVBS-MgEGTA and 
mixed with compstatin serial dilutions to a final concentration of 30%. Serum diluted in 
GVBS-MgEGTAandGVBS (containing 20 mM EDTA) were used as positive and negative 
controls for complement activation, respectively. Dilutions were preincubated for 15 min at 
room temperature, transferred to ELISA plates, and incubated for 1 h at 37° C. Generation of 
C3b and C5b-9 were assayed using horseradish peroxidase (HRP)-conjugated anti-C3 (MP 
Biomedicals, Solon, OH, USA) and anti-C5b-9 aE11 (Abcam, Cambridge, MA, USA), 
respectively. Plates were washed and incubated with either anti-C3-HRP (1:5000 in 1% 
BSA/PBS-T) or anti-C5b-9 (1:1000 in 1% BSA/PBS-T) for 1 h at 37 °C. For C5b-9 
detection, primary antibody incubation was followed by incubation with anti-mouse-HRP 
(BioRad, Hercules, CA, USA) for 1 h at 37 °C (1:5000 in 1% BSA/PBS-T). Bound C3b and 
C5b-9 were quantified using a 3,30,5,50-tetramethylbenzidine substrate solution containing 
urea hydrogen peroxide in 0.11 M sodium acetate buffer, followed by a 1 N H2SO4 acid 
stop. Plates were measured spectrophotometrically at 450 nm. Percent inhibition of C3b and 
C5b-9 depositionwas plotted against peptide concentration and the datawas fitted to a logistic 
dose response curve with Prism software (GraphPad, San Diego, CA, USA) to determine 
IC50 values. 
 
2.3. Hemolytic assays 
Inhibition of complement was also measured via lysis of erythrocytes. Rabbit erythrocytes 
(Complement Technology Inc., Tyler, TX, USA) were washed in PBS and resuspended in 
veronal buffered saline with 5 mM MgCl2 and 10 mM EGTA (VBSMgEGTA). Peptide and 
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serum dilutions were prepared as described above, and 1 x 10
7
 erythrocytes were added to 
each serum/peptide mixture. Erythrocytes diluted in sterile deionized water and in VBS-
MgEGTA were used as positive and negative controls for lysis, respectively. Plates were 
incubated for 20 min at 37° C, and centrifuged at 2500 x g for 10 min. Supernatants were 
diluted 1:2 and absorbance was measured at 405 nm. 
 
2.4. RPE cell culture  
The in vitro drusen biogenesis model was employed as previously described (Johnson et al., 
2011). Human fetal RPE cells (Advanced Bioscience Resources, Alameda, CA) were 
cultured on Millipore HA porous supports (Millipore, Cat # PIHA 01250) in Miller medium 
(Maminishkis et al., 2006) supplemented with 5% fetal calf serum (FCS). Cultures derived 
from three different donor eyes were employed. Cells were rinsed with warm, sterile PBS 
and the insert membrane was excised with a scalpel and cut into small (~4 mm
2
) pieces 
which were placed in wells of a 96-well plate. To minimize effects of inter-culture 
variability, samples prepared from a single membrane were utilized for each experiment. The 
samples were rinsed in PBS and then exposed individually to the library of compstatin family 
peptides at 1 M in FCS-free Miller medium containing 10% human complement serum 
(Innovative Research, Cat # IPLA-CSER AB, Lot # L12402). In preliminary experiments, 
compstatin family Peptides I, III, VI, VII, VIII, IX, and Parent (Table 1), were tested in the 
RPE cell assay at 100 M and titrated by C5b-9 ELISA over a concentration range of 0.04-
130 M (data not shown). The 1 M concentration employed was selected based on these 
results, showing it to be in the linear range of inhibitory concentrations. Also from this 
assessment, we selected as most promising Peptide VI, as well as Peptides I and III, for 
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further studies. Peptides I and III were chosen for comparative studies to Peptide VI, because 
they contain an arginine residue at position 1. Our goal was to determine whether peptides 
containing arginine at position -1 (Peptide VI) or at position 1 (Peptides I and III) were 
potent complement inhibitors using the RPE cell assay and had improved aqueous solubility 
compared to previously known potent analogs. Negative control cells were exposed to Miller 
medium (+5% FCS; positive control cells were exposed to Miller medium +10% human 
complement serum without inhibitory peptides. Experimental and control medium/inhibitor 
solutions were pre-mixed on a rocker at room temperature for 30 min, then warmed to 37° C, 
prior to placement on the samples and incubation for 24 h at 37° C in a 7.0% CO2 incubator. 
Following the incubation period, the medium was removed and stored frozen prior to ELISA 
analysis. The cell/membrane samples were rinsed in PBS, fixed in cold 4% 
paraformaldehyde (PFA) in PBS for 20 min, and stored in 0.4% PFA until use in 
immunohistochemical assays. 
 
2.5. Immunohistochemistry 
Fixed samples were rinsed several times in PBS, embedded in 10% agarose (Type XI, 
Sigma-Aldrich, Cat # A3038) and sectioned at 100 m on a vibratome. Sections were 
blocked with normal donkey serum (1/20 in PBT: PBS containing 0.5% bovine serum 
albumin and 0.1% Triton X-100) overnight at 4° C. The sections were then co-incubated in 
two primary antibodies (polyclonal goat anti-ApoE, Millipore Cat # AB947; 1/1000 in PBT, 
and mouse monoclonal anti-C5b-9 aE11, Dako Cat # MO777; 1/200 in PBT) overnight at 4° 
C, then rinsed in PBT and co-incubated in secondary antibodies (Alexa Fluor 546-conjugated 
donkey anti-goat IgG and Alexa Fluor 488-conjugated donkey anti-mouse IgG, both 1/200 in 
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PBT; LifeTechnologies Cat # A-11056 and # A-21202) overnight at 4 °C. Sections were 
rinsed in PBT, stained with Hoechst 33342 (Life Technologies Cat # H3570), and mounted 
on slides with Prolong Gold (Life Technologies Cat # P36930). 
 
2.6. Confocal imaging and analysis 
Samples were imaged on an Olympus FV1000 confocal laser scanning microscope. A total of 
154 single-plane images were acquired at a resolution of 1024 x 768 pixels and the digital 
image files were saved in 24-bit tiff format. Digital image analysis was performed with 
MetaMorph software (Molecular Devices, Sunnyvale, CA). For the analysis, a standard 
measurement region, which included both the RPE cell monolayer and all of the adjacent 
subcellular deposits, was applied to each image. The Set Threshold Color Tool was utilized 
to analyze each color channel separately; the threshold tool creates a boundary around the 
objects being measured (i.e. sub-cellular deposits) on the basis of color intensity. The upper 
threshold was set so that the entire deposit area was selected; then the lower threshold was set 
to exclude background fluorescence. These settings allowed the isolation of deposit 
associated fluorescence and independent measurement of the area and intensity of C5b-9 
immunofluorescence in the green channel and ApoE immunofluorescence in the red channel 
(see Table S1). The ApoE threshold was standardized using the negative control samples. 
The positive control samples, which contained the highest levels of C5b-9 immunoreactivity, 
were used to standardize the C5b-9 threshold. Positive and negative control standards and the 
associated thresholds were independently established for each cell line for each experiment. 
The sum of the pixel intensities within the threshold limits (integrated area) was used in 
statistical analyses. For each image, the integrated area of C5b-9 was normalized to the ApoE 
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area and the ratio of C5b-9/ApoE intensity was expressed as a percentage of the positive 
control sample. Statistical analysis of the data from each of the treatment groups was 
performed using a one-way ANOVA calculated using Tukey’s test for multiple comparisons. 
A p value < 0.05 was considered to be of statistical significance. To assess variability in the 
amounts of sub-cellular deposits, the ApoE fluorescence data was analyzed and area values 
for the seven treatment groups were compared. This analysis demonstrated that there was not 
a statistically significant difference in the ApoE deposit load among the seven treatment 
groups examined [F(6,14) = 0.363, p = 0.89] (Fig. S1). 
 
2.7. Soluble C5b-9 ELISA of the RPE cell-based assay medium 
Experimental medium solutions were diluted 1/625 in assay diluent and quadruplicate 
ELISAs were performed using an OptEIA C5b-9 ELISA kit (BD Biosciences, Cat # 558315). 
Plates were read at 450 nm, with absorbance at 570 nm subtracted for wavelength correction, 
on a BioRad Benchmark plate reader. C5b-9 concentrations were calculated using a standard 
curve generated using purified human C5b-9. Data was expressed as a percentage relative to 
the positive (human serum only) control. Means and standard errors for data from the three 
RPE donor cells were calculated and graphed using SigmaPlot 11.0 (Systat Software, San 
Jose, CA), and one-way ANOVA was calculated using Tukey’s test for multiple 
comparisons. 
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2.8. RP-HPLC study 
The effect of the hydrophobic content of compstatin family peptides on relative lipophilicity 
was evaluated using RP-HPLC, a widely applied indirect technique for the determination of 
the lipophilicity of drugs and drug candidates (Valkó, 2004; Henchoz et al., 2009). The 
determination of logP by RP-HPLC is based on the measurement of the retention factor k 
between the mobile and stationary phase (Eq. (1)) of the investigated compound (Berthod 
and Carda-Broch, 2004)  
        
     
  
   (1) 
where tR is the retention time of the analyte, and t0 is the elution time of an unretained 
analyte. The logarithm of the retention factor is linearly correlated with the logarithm of the 
partition coefficient  
               (2) 
where a and b are the slope and intercept of the linear equation. The determination of logP 
values requires calibration using structurally related compounds, and is beyond the scope of 
this study. Instead the logk values were used to indicate the relative lipophilicities of this 
compstatin peptide family. HPLC experiments were carried out using an Agilent 1100 HPLC 
with UV detection at 280 nm at 25 °C. Separations were performed on a Waters (Milford, 
MA) 4.6 x 150 mm XTerra MS C18 column with 5 mm pore size using a mobile phase of A: 
10 mM phosphate buffer pH = 7.4 containing 1% TFA, and B: acetonitrile. The purity of the 
peptides was verified by an isocratic separation at 28% B and a flow rate of 1 mL/min. 
Solutions containing 0.6-0.8 mg/mL of Peptides I, III, VI, IX and the Parent peptide were 
prepared in methanol and diluted 5-times with the eluent. All five peptides eluted as single 
peaks indicating a high degree of purity (Fig. S2). For the determination of the relative 
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lipophilicities a solution containing each of the peptides was prepared from the stock 
solutions and injected in triplicate. Isocratic elution at 24% B and a flow rate of 1 mL/min 
resulted in separation of the Peptides I, III, VI, IX and Parent (Fig. S3). A 0.5 mg/mL 
solution of aspartic acid was used as the unretained analyte for the determination of the 
column dead time, 1.439 ± 0.003 min. Sodium phosphate monobasic, aspartic acid, methanol 
and acetonitrile were obtained from Fisher Scientific (Pittsburgh, PA). Trifluoroacetic acid 
(TFA) was purchased from Acros (Geel, Belgium). HPLC-grade Burdick and Jackson water 
was used for the HPLC analysis (Morristown, NJ). 
 
2.9. NMR study 
NMR spectroscopywas used to confirm peptide purity. Although the HPLC separations 
suggested that the peptides were of high purity as a single chromatographic peak was 
observed for each sample, the possibility of coelution of the desired peptide and structurally 
related impurities cannot be discounted. Because of the sensitivity of chemical shifts to subtle 
structural changes, 1H NMR spectroscopy provides an excellent measure of peptide purity. 
1H NMR spectra were acquired for separate solutions of each peptide prepared by dissolving 
1mg samples into 600 mL 50 mM phosphate buffer containing 10% D2O and 0.4 mM 2,2 
dimethyl-2-silapentane-5-sulfonate-d6 sodium salt (DSS) as a reference compound. The pH 
of the phosphate buffer was set to 6.5 using NaOD. 
1
H NMR spectra were recorded at 22° C 
with a Bruker Avance spectrometer operating at 1H frequency of 600.01 MHz using a triple 
resonance inverse probe. Excitation sculpting was used for water suppression (Bruker pulse 
program zgesgp) (Hwang and Shaka, 1995). Spectra were collected into 32,768 points using 
64 scans with a spectral window of 12 ppm, were processed in 65,536 points and multiplied 
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with an exponential function equivalent to 0.5 Hz line broadening. Deuterium oxide and 
NaOD were obtained from Cambridge Isotope Laboratories (Andover, MA), DSS was 
purchased from Sigma Chemical Company (St. Louis, MO). Water was HPLC grade from 
Burdick & Jackson (Honeywell, Morristown, NJ). The samples used to measure C3b and 
C5b-9 ELISAs and hemolytic lysis assays presented here (Peptides I, III, VI, IX, and Parent) 
were tested with HPLC and NMR, as discussed above and were found to be pure (Figs. S2-
S4). The samples used for the RPE cell assays were from an older preparation and some 
appeared to have an impurity in HPLC experiments, which was not due to aggregates. We 
have estimated the impurity populations of the old Peptides III and VI was 15% and 33% 
using the HPLC chromatograms. Nevertheless, the relative potencies of the peptides were 
similar in C3b ELISA experiments using the two sample preparations. 
 
2.10. Molecular dynamics simulations 
Molecular dynamics simulations were performed for Peptides III and VI, using explicit water 
solvation as described elsewhere (Tamamis et al., 2010, 2011, 2012). The molecular 
mechanics program CHARMM c35b5 (Brooks et al., 2009) was used for the simulations, 
with the CHARMM22 all-atom force field (MacKerell et al., 1998), including a CMAP 
backbone 4/j energy correction (Mackerell et al., 2003) and indole parameters (Macias and 
MacKerell, 2005). Match server was used to derive the topology and parameters for the 
methylated tryptophan aromatic ring (Yesselman et al., 2012). The simulation protocol and 
force field specifications were as described in Tamamis et al. (2010, 2011), 2012). As in 
Tamamis et al. (2012), loop C3 369e378 was unrestrained during the simulations since it is in 
proximity to the N terminus of the peptides. For Peptide III, five 7-ns trajectories, starting 
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from the same initial conformation with different equilibration times, were generated to a 
total of 35 ns simulation time. For Peptide VI, five 10-ns trajectories, starting from the same 
initial conformation with different equilibration times, were generated to a total of 50 ns 
simulation time. A total of 700 and 1000 snapshots were analyzed for III and VI, 
respectively, extracted every 50 ps per trajectory. Percent occupancies were calculated for 
hydrogen bonds, as well as averaged intermolecular interaction energies, using homemade 
scripts. Molecular visualization was performed using the program VMD (Humphrey et al., 
1996). 
 
2.10.1. Initial coordinates 
For Peptide III, the protein and ligand atoms (with the exception of Arg1 side chain), were 
initially placed according to the crystallographic structure of the Ac-V4W/H9A Compstatin: 
human C3 complex (PDB code 2QKI) (Janssen et al., 2007). The Arg1 side chain was placed 
with the aid of program SCWRL 4.0 (Krivov et al., 2009). For Peptide VI, the protein and 
ligand atoms (with the exception of the Arg-1 side chain) were initially placed at a structure 
taken from the simulation of the Ac-SS-ICV WQDWGAHRCT-NH2: human C3 complex 
(Tamamis et al., 2012); that simulation itself was based on the crystallographic structure of 
the Ac-V4W/H9A Compstatin: human C3 complex (PDB code 2QKI) (Janssen et al., 2007). 
The employed structure had the lowest association free energy, as determined in the 
Molecular Mechanics-Generalized Born/Surface Area (MM-GBSA) approximation (see Eqs. 
(4,5) of Tamamis et al. (2012)). The Arg-1 side chain was placed with the aid of program 
SCWRL 4.0 (Krivov et al., 2009). 
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2.10.2. Computation of interaction free energies of protein and ligand residue pairs 
The interaction free energies between two (R and R0) residues are computed in the MM 
GB/SA approximation, as described (Kieslich et al., 2012; Tamamis et al., 2012) using the 
equation: 
 (3) 
The first and second group of terms on the right-hand side of Eq. (3) describe, respectively, 
polar and nonpolar interactions between R and R0, where Coul denotes Coulombic, GB 
denotes generalized Born, S is the solvent accessible surface area, and s is a surface tension 
coefficient. In our calculations, R corresponded to a ligand residue and R’ corresponded to a 
protein residue. To compute the GB term (Im et al., 2003) term in Eq. (3), we included all 
protein and ligand atoms and set the charge to zero for atoms other than those belonging to 
residues RR0, R and R0 , respectively, in each calculation of the terms on the right-hand side 
terms of Eq. (3). The last term contains the difference in solvent accessible surface areas of 
groups R and R0 in the complex and unbound states. Free-energy values were averaged over 
all trajectories. We decomposed the total interaction free energies into polar and nonpolar 
interaction free energy components and the results are presented in two dimensional maps. 
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Results 
 
3.1. Peptide design 
The design of the new compstatin peptides was inspired by our recent studies that include (i) 
the application of two-stage computational frameworks for protein design that are based on 
sequence selection, fold specificity, and approximate binding affinity calculations (Bellows 
et al., 2010a); (ii) rational design based on structural/physicochemical analysis–activity 
relations (López de Victoria et al., 2011); and (iii) structural and binding analysis using 
molecular dynamics simulations (Tamamis et al., 2012). These studies identified new active 
compstatin family peptides with novel features, such as introduction of tryptophans at 
positions 1 and 13, arginine at position 1, and an N-terminal di-serine extension. Some of 
these analogs suffer from solubility/aggregation problems, owing to increased 
hydrophobicity content conferred by the presence of up to four tryptophans. Nevertheless, 
these studies revealed three new sites of optimization in the compstatin peptide sequence at 
positions 1, 0, and -1. We reasoned that incorporation of polar amino acids at positions 1, 0, 
and -1, while maintaining the amino acids that are involved in hydrophobic contacts with C3, 
would aid in balancing the polarity/hydrophobicity ratio and in improving solubility. The 
choice of amino acids for positions 1, 0, and -1 was based on our previous molecular 
dynamics simulations (Tamamis et al., 2012) and supported by new molecular dynamics 
simulations, such as those described below, for Peptides III and VI. Methodological details 
are given elsewhere for the two-stage computational frameworks (Bellows et al., 2010a, 
2010b; Bellows-Peterson et al., 2012), biochemical assays (López de Victoria et al., 2011), 
and MD simulations (Tamamis et al., 2010, 2011; 2012). Table 1 shows the sequences of the 
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peptides studied. With the exception of Parent, the sequences of Table 1 contain either Trp or 
methylated-Trp at position 4 and Ala at position 9. The new sequences include N-terminal 
replacements of Ile with Arg (Peptides I and III), as well as N-terminal extensions (Peptides 
IV, VIeVIII). The latter include the SereSer (Peptide IV and VIII) and ArgeSer (Peptides VI 
and VII) extensions. Two of the ArgeSer extension sequences also incorporate N-terminal 
replacements of Ile with Arg (Peptides VII and VIII). These sequences are modeled after the 
sequence of the most potent peptides comprised entirely of natural amino acids (control 
Peptide IX; (Mallik et al., 2005)) and the most potent peptide to-date, which is similar to 
Peptide IX but with methylated-Trp at position 4, with methylation being attached at the 
indole nitrogen (Katragadda et al., 2006). Four of the new sequences in Table 1 incorporate 
methylated-Trp at position 4 (Peptides III, VIeVIII), in an effort to maintain high potency, 
and six contain polar amino acids at positions -1, 0, and 1 (Peptides I, III, IV, VI–VIII). We 
also tested two more sequences that contain hydrophobic amino acids (Trp or methylated 
Trp) at the N-terminus or N terminal extension for contrasting comparisons (Peptides II and 
V), which showed reduced solubilities. The incorporation of tryptophans at the amino 
terminus was suggested by our recent previous work (Bellows et al., 2010a; López de 
Victoria et al., 2011; Tamamis et al., 2012). In preliminary C3b ELISA experiments, 
Peptides I-IX demonstrated comparable potencies, within up to 3-fold IC50 differences. We 
selected for preliminary RPE cell culture experiments Peptides I, III, VI, VII, and VIII, 
which contained Arg at the N-terminus or Nterminal extension, together with control Peptide 
IX and Parent. The remaining peptides were discarded because of solubility issues (Peptides 
II and V) or because they did not contain Arg at the Nterminus or N-terminal extension 
(Peptides II and IV). Based on the preliminary RPE cell assay studies (see Materials and 
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methods) a reduced number of peptides (Peptides I, III, and VI) was selected, for more 
quantitative C3b and C5b-9 ELISA, hemolytic assay, and RPE cell-based assay studies, 
together with control Peptide IX and Parent for comparison. These studies are described in 
detail below. 
 
3.2. Analysis of complement inhibition by C3b and C5b-9 ELISA, and erythrocyte lysis 
assay 
Since compstatin family peptides are known to selectively inhibit the complement alternative 
pathway (AP), we performed ELISAs and erythrocyte lysis assays to examine AP inhibition. 
In all assays, MgEGTAwas used to chelate Ca
2+
 ions required for classical/ lectin pathway 
complement activation, while providing Mg
2+
 necessary for AP activation. ELISAs allow for 
direct detection of C3b and C5b-9 formed during AP activation, while erythrocyte lysis 
assays provide a functional assessment of AP-mediated hemolysis in serum. Fig. 1 shows the 
C3b and C5b-9 ELISA and erythrocyte lysis data for Peptides I, III, VI, IX, and Parent. Table 
2 summarizes the IC50 values derived from the three different assays. Parent exhibited 
significantly less complement inhibition than all other peptides in all three assays. Newly 
designed peptides (Peptides I, III, and VI) showed similar IC50 values to Peptide IX, with 
Peptide I having a slightly higher IC50 than the others in all cases. The relative potencies of 
the peptides, based on the measured IC50 values, are consistent across all three assays 
(Peptide III ~ Peptide VI ~ Peptide IX > Peptide I > Parent). Based on the assay conditions 
used in this study, peptides inhibited C5b-9 formation with moderately better efficacy than 
formation of C3b, while slightly higher concentrations were necessary to inhibit AP-
mediated hemolysis. It is also noteworthy that while C3b and C5b-9 inhibition by Parent was 
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about 10- to 15-fold less than other peptides in ELISA, only a 4- to 6-fold difference was 
observed for hemolysis. 
 
3.3. Complement inhibition in the RPE cell model 
Exposure of RPE cell cultures to human serum leads to complement activation, as evidenced 
by the formation of sub-cellular deposit-associated C5b-9 (Johnson et al., 2011). Deposit-
associated C5b-9 immunofluorescence was quantified using confocal microscopy and 
normalized to the fluorescence signal for ApoE (a ubiquitous deposit marker). In the 
presence of active compstatin family peptides, the amount of deposit-associated C5b-9 is 
reduced, proportionally to the peptide potencies. Fig. 2 shows examples of confocal 
immunofluorescence images of sub-RPE deposit-associated C5b-9. Table 3 and Fig. 3 show 
the results of the RPE cell experiments for the aforementioned peptides. Peptides III, VI, and 
IX showed significantly more complement inhibition than Parent, reducing the C5b-9 
deposits to approximately 15–20% of the positive control (human serum without inhibitory 
peptides). The effect of methylated-Trp4 in complement inhibition is evident when 
comparing the confocal imaging data of Peptides III and VI against those of Peptide I, which 
contains unmethylated Trp (Table 1). The confocal microscopy data reveal a large range of 
inhibition at the level of the sub-RPE deposits, and markedly discriminate the potencies of 
the peptides. The one-way ANOVA revealed a significant effect of the complement 
inhibitory peptides on deposit-associated C5b-9 formation [F(5,12) = 26.4, p < 0.001]. In the 
presence of Parent, deposit associated complement activation was reduced to 83% of the 
positive control (mean ± S.E.M. = 83.2 ± 5.9), but this difference was not statistically 
significant. However, Peptides I (55.3 ± 12.3), III (20.0 ± 6.8), VI (14.9 ± 5.6), and IX (21.1 
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± 6.3), all exhibited significantly more inhibition, and all were statistically different from 
Parent (p < 0.001). Peptides III, VI, and IX exhibited the greatest potencies and were not 
significantly different from each other. Overall, the relative potencies derived from the RPE 
cell-based assay, C3b and C5b-9 ELISAs, and hemolytic assay experiments are in agreement 
and they follow the order Peptide III w Peptide VI w Peptide IX > Peptide I > Parent. 
 
3.4. Analysis of complement inhibition by soluble C5b-9 ELISA of the RPE cell-based 
assay medium 
We also performed C5b-9 ELISAs of the RPE cell assay medium (Table 3, Fig. 4). A narrow 
range of inhibitionwas observed in these C5b-9 data, compared to the confocal microscopy 
data, likely reflecting background turnover of complement in the liquid phase as opposed to 
that directly associated with the sub-RPE deposits. Nevertheless, the one-way ANOVA 
showed a significant effect of the inhibitory peptides on soluble C5b-9 formation [F(5,12) = 
144.2, p < 0.001]. This parallel analysis of soluble C5b-9 in the experimental medium 
solutions also showed the level of inhibition by Parent to be less than that of the experimental 
peptides. In the presence of Parent, C5b-9 levels were reduced to 89% of the positive control 
(mean ± S.E.M. = 88.5 ± 0.76, p = 0.011). All of the experimental peptides were more 
inhibitory, I (61.4 ± 2.3), III (50.0 ± 0.8), VI (44.6 ± 3.2), IX (51.9 ± 2.2) and all were 
statistically different from Parent (p < 0.001). 
 
3.5. Lipophilicity measurements using RP-HPLC 
We used RP-HPLC to measure the hydrophobicity/lipophilicity content of the compstatin 
family peptides. The retention of a compound in RP-HPLC depends on its 
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hydrophobicity/lipophilicity content, and is correlated to the octanol-water partition ratio 
(Berthod and Carda-Broch, 2004; Valkó, 2004; Henchoz et al., 2009). Lipophilicity describes 
the partitioning of a compound between an aqueous and a lipidic/hydrophobic environment, 
and is an essential physicochemical parameter to determine pharmacokinetic behavior 
according to ADME (absorption, distribution, metabolism, excretion) characterization. 
Because the compstatin family peptides consist of a hydrophobic and a polar surface 
(Morikis and Lambris, 2002; Morikis et al., 2002, 2004), their ability to bind to the 
hydrophobic cavity of C3, while maintaining a solvent-exposed face has been evaluated here 
as lipophilicity content, measured by RPHPLC. In addition, lipophilicity is inversely 
proportional to aqueous solubility, and therefore can be used to estimate solubility of the 
peptides in their free (unbound) state. Table 4 shows the retention times (tR) and retention 
factors (k) for Peptides I, III, VI, IX, and Parent. These, and data for the whole set of peptides 
of Table 1 (not shown), suggest that the major factors governing hydrophobicity of the 
peptides are the number of tryptophan and methylated-tryptophan residues in the sequence, 
which increases hydrophobicity, and the net charge of the peptide, which decreases 
hydrophobicity. Peptides containing two or more tryptophans are the most lipophilic, and 
introduction of arginines in the sequence results in decreasing lipophilicity. Parent is the 
least lipophilic (Table 4). The relative lipophilicities of Peptides I, III, VI, IX, and Parent are 
inversely consistent with solubilities as determined via concentration measurement 
(absorbance at 280 nm) of saturated peptide solutions, with Peptides I, III, and Parent having 
approximate aqueous solubilities of >1 mM, Peptide VI > 500 M, and Peptide IX < 500 
M. 
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3.6. Molecular dynamics simulations 
Recent MD studies have provided insights into the role of arginine at position 1 (Peptide I, 
Table 1) and the diserine extension at positions 0 and -1 (Peptide IV, Table 1) (Tamamis et 
al., 2012). The MD studies have shown that an Arg1 substitution (Peptide I) maintains the 
interactions with C3 observed in control Peptide IX, with a new salt bridge being observed 
between Arg1 and C3 Asp349 (Tamamis et al., 2012). As the presence of a methyl group at 
Trp4 has been reported to enhance binding affinity compared to control Peptide IX 
(Katragadda et al., 2006), we performed MD simulations of C3-bound Peptide III, which has 
a methyl group at Trp4 compared to Peptide I. Similarly, Peptide IV also maintains the 
interactions with C3 observed in control Peptide IX, with a new hydrogen bond being 
observed between Ser0 and C3 Asn390 (Tamamis et al., 2012). These additional interactions 
involving N terminal residues, contribute to increased computed binding affinity with regard 
to Peptide IX-C3 complex. Critical analysis of the contacts of the diserine extension with C3 
residues led us to replace serine by arginine at position -1, and additionally investigate 
Peptide VI in complex with C3 using MD simulations. Besides increased intermolecular 
contacts and computed binding affinities, the introduction of the polar-charged arginine 
residues at positions 1 (Peptide III) or -1 (Peptide VI) also contribute to increased peptide 
solubilities, a desired property of the new designs. We performed MD simulations to 
understand the molecular interactions of the two most promising new peptides (Peptides III 
and VI). Fig. 5 shows representative MD structures of Peptides III, VI and control Peptide 
IX, depicting intermolecular hydrogen bonding patterns and nonpolar pockets within the 
binding site. Typically, the 13-residue compstatin peptides form intermolecular contacts with 
four C3 sectors (Tamamis et al., 2010, 2012), as is the case for control Peptide IX (Fig. 5E 
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and F). For Peptide III, the incorporation of a methyl group at Trp4, in conjunction with an 
Ile1Arg substitution, leads to additional intramolecular interactions between peptide residues 
and additional intermolecular peptide-C3 interactions, compared to control Peptide IX. The 
methyl group of Trp4 fits between the disulfide bridge Cys2eCys12 of the ligand and 
residues His392 and Pro393 of C3. Owing to the favorable Cys2-methylated-Trp4 
interaction, the N-terminus of the ligand is displaced (Fig. 5A and B, towards segments 
colored in blue, orange, and green on the right-hand side of each panel) with regard to 
Peptide IX (Fig. 5C and D); the root mean square displacement of atom Arg1 C is 2.3 Å. 
Therefore, the side chain of Arg1 of Peptide III is favored to form a new highly interacting 
salt bridge with Glu372 of the fifth C3 sector (Fig. 5A; Table 5). This finding is in contrast to 
the Arg1-Asp349 salt bridge, which is present in the absence of methyl group at Trp4 
(Peptide I) (Tamamis et al., 2012). For Peptide VI, the two-residue Arg-Ser N-terminal 
extension forms additional contacts with a fifth C3 sector (Fig. 5C and D; Table 5). These 
contacts include a strong salt bridge between the side chains of Arg-1 and C3 residue Glu372 
of the fifth sector, and contribute to increased stability of the complex compared to control 
Peptide IX (Tamamis et al., 2010). Fig. 6 shows the interaction free energy maps of 
intermolecular interactions between protein residues and ligand residues. Panels 6A, B 
present the polar and Panels 6C, D present the nonpolar interaction free energies of Peptides 
III and VI, respectively. The strongest pairwise intermolecular interactions, are formed 
between the newly introduced Arg1/Arg-1 residues of Peptides III and IV, respectively, and 
C3 Glu372 (Fig. 6). Similarly to Peptide III, the Trp4 methyl group of Peptide VI fits 
between the disulfide bridge residues Cys2-Cys12 of the ligand and residues His392 and 
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Pro393 of C3. It is worth noting that Il-1 of Peptide VI is not destabilized from its initial 
position as it is attracted to C3 residues Pro347 and Asn390 on the one side, and C3 residues 
Leu454, Leu492, as well as compstatin residue His10, on the other side. 
 
Discussion 
This study was motivated by the impetus to design and identify new compstatin analogs with 
improved binding, complement inhibition, and solubility characteristics. The scope of the 
design was two-fold; first, to promote binding to the target protein C3 through key amino 
acid side chain interactions, and second, to enhance solubility compared to previously known 
compstatin analogs, by improving the peptide polarity/hydrophobicity ratio. Our design is 
based on the application of two-stage computational frameworks (Bellows et al., 2010a), use 
of biochemical binding and inhibitory assays (López de Victoria et al., 2011), and MD 
simulations of peptide-C3 complexes (Tamamis et al., 2012), which have demonstrated that 
either an arginine substitution at position 1 or a diserine extension at the N-terminus lead to 
novel binding contacts with C3. In the present study, the introduction of an arginine either at 
position 1 or at position -1 of N-terminal dipeptide extensions, in conjunction with a presence 
of methyl group at the side chain of Trp4, both promote the formation of salt bridges with 
Glu372, located on C3. A total of ten peptides were studied, three of which are N-terminal 
replacements (Peptides I–III), five are N-terminal extensions (Peptides IV–VIII), and two are 
positive controls (Peptide IX and Parent; Table 1). One peptide from the N-terminal 
replacements and one from the N-terminal extensions were introduced in a previous study 
(Peptide I and Peptide IV, respectively (Tamamis et al., 2012)). From the eight newly 
designed peptides, four have tryptophan at position 4 (Peptides I, II, IV, and V) and four have 
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methylated-tryptophan at position 4 (Peptides III, and VIeVIII). The design of six out of 
eight new analogs was aimed at increasing polarity at the N-terminal sequence segment 
(Peptides I, III, IV, and VI–VIII), whereas the remaining two analogs were designed with an 
aim of increasing hydrophobicity and were used for comparison (Peptides II and V). We used 
two compstatin peptides as controls; Parent represents the unmodified sequence of 
compstatin, with non-acetylated N-terminus, valine at position 4 and histidine at position 9 
(Sahu et al., 2000). The Parent control is the only nonacetylated peptide in this study (Table 
1). Control Peptide IX (Mallik et al., 2005) represents the most active known compstatin 
analog consisting only of natural amino acids prior to this study. Its sequence is similar to 
Parent, but it is acetylated at the N-terminus and has tryptophan and alanine replacements at 
positions 4 and 9, respectively. Taking into account that the most potent compstatin analog 
reported to date contains a methylated-tryptophan at position 4 (Katragadda et al., 2006), we 
decided to incorporate methylated-Trp4 in half of the eight new peptides presented here 
(Table 1). The rationale for introducing novel features in the sequence of compstatin family 
peptides is based on the need for improving solubility and eliminating aggregation in 
aqueous solutions. The previously reported most potent peptide to date, similar to Peptide IX 
but with methylated-Trp4, is known to possess precipitation characteristics and exhibits 
intravitreal deposit formation (Chi et al., 2010; Yehoshua et al., 2011; Qu et al., 2013). 
Consistent with these reports, we observed that this peptide exhibited low solubility and 
visible precipitation, based on concentration measurements of saturated aqueous solutions of 
the peptide (See Materials and methods). In addition, aggregation of this peptide prohibited 
its testing in RPE-based cell assays. This peptide is not the only compstatin analog with 
solubility problems; Peptide IX is also not highly soluble and is prone to aggregation at high 
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concentrations. Therefore, Peptides I, III, IV, and VI–VIII were designed to contain polar 
amino acids at positions -1, 0, and 1. The effect of polar amino acids on the lipophilicity of 
these peptides was assessed using RP-HPLC experiments, and was found to be in agreement 
with our design rationale. Saturating concentrations measured prior to ELISA and hemolysis 
screening confirmed relative solubilities of newly designed and control peptides. In addition 
to solubility enhancement, we sought to identify analogs exhibiting potent complement 
inhibition. While residues at the N-terminus (and in N-terminal extensions) were optimized 
for peptide solubility, key amino acids contributing to binding (Janssen et al., 2007; Tamamis 
et al., 2012) are maintained in the peptide sequences. Hydrophobicity was shown to be 
important for compstatin peptide binding to C3 in early studies based on the structure of free 
parent compstatin (Morikis et al., 1998; Sahu et al., 2000; Morikis and Lambris, 2002; 
Morikis et al., 2002; Klepeis et al., 2003; Soulika et al., 2003; Klepeis et al., 2004; Morikis et 
al., 2004; Mallik et al., 2005; Mallik and Morikis, 2005; Morikis and Lambris, 2005), and 
more recent studies based on the structure of a C3cbound compstatin analog (Janssen et al., 
2007; Ricklin and Lambris, 2008; Magotti et al., 2009; Qu et al., 2009; Bellows et al., 2010a; 
Tamamis et al., 2010; López de Victoria et al., 2011; Tamamis et al., 2012; Qu et al., 2013). 
However, as increased hydrophobic amino acid content resulted in higher potency, it also 
brought undesirable solubility problems. Based on critical analysis of the structural data from 
the MD trajectories and the results of initial C3b ELISA studies, we selected Peptides I, III, 
and VI, for further evaluation of their inhibitory activities using C3b and C5b-9 ELISA and 
functional hemolytic assays. Peptide IX and Parent were used as controls for high and low 
levels of complement inhibition, respectively. ELISA results showed potent inhibition by 
newly designed peptides, with similar C3b and C5b-9 inhibition levels as observed for 
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positive control Peptide IX. Parent exhibited at least 10-fold less inhibition. In functional 
hemolytic assays, we observed a similar trend. Irrespective of the magnitudes of complement 
inhibition in the various assays used in this (and other) studies, the relative efficacies of 
Peptides I, III, VI, IX, and Parent remained consistent. We also used a novel human RPE cell 
assay and C5b-9 ELISA of the cell culture medium to evaluate the efficacy of the newly 
designed compstatin family peptide inhibitors of the complement system. The RPE cell assay 
provides an experimental model for testing complement inhibition in a cell environment that 
mimics AMD pathogenesis, and therefore is superior to in vitro ELISA-based complement 
inhibition assays. Confocal image analysis of C5b-9 immunofluorescence from the RPE 
experiments provides strong evidence for the efficacy of Peptides III, VI, and IX, with all of 
them being equally potent within experimental error. Our data show that methylation of Trp4 
in combination with incorporation of Arg1 or Arg-1 at the N-terminus (Peptides III and VI, 
respectively) produces up to 85% complement inhibition at the sub-RPE deposit level. 
Perhaps this is an adequate level of inhibition, as it is not desirable to completely abrogate 
the immune response benefits of complement function in the clinic. Peptide IX (positive 
control) showed statistically similar complement inhibition, whereas Parent was much less 
effective. Given the improved solubility properties of Peptides III and VI, they may be good 
alternatives to the currently most potent peptide (possessing methylated-Trp4), which 
exhibits aggregation at high concentrations in aqueous environments. In addition to improved 
solubility/lipophilicity properties, Peptides III and VI introduce a novel feature in the binding 
mechanism to C3, through the formation of intermolecular salt bridges between arginine at 
positions 1 or -1 and Glu372 of C3. These salt bridges provide additional stabilization to the 
C3–Peptide III and C3–Peptide VI complexes, compared to other known complexes of C3 
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with compstatin analogs. The novelty of the salt bridge interactions arises from the fact that 
Glu372 lies outside the binding pocket that was previously determined experimentally and 
computationally (Janssen et al., 2007; Tamamis et al., 2010, 2012). Therefore, incorporation 
of Arg1/-1 in the sequence of compstatin analogs is an additional contributing factor to the 
steric hindrance of the convertase binding to C3.  
 
Conclusions 
Our study presents a proof-of-concept demonstration of the utility of a novel human RPE 
cell-based assay in quantifying complement inhibition in an AMD-like environment. Given 
the species specificity of compstatin for human and primate C3, but not for murine and other 
non-primate C3 (Sahu et al., 2003; Tamamis et al., 2010), and therefore lack of non-primate 
animal models, the RPE cell assay may be a viable alternative for initial screenings in 
advance of testing in primates in preparation for clinical trials. The study also validates our 
computational protocol for the design of new potent complement-inhibiting peptides of the 
compstatin family. We show that incorporation of polar amino acids at the N-terminus or N-
terminal extension, with arginine at positions 1 or -1, improves polarity/hydrophobicity ratio 
and therefore improves solubility/lipophilicity properties. In addition, the MD data provide 
mechanistic evidence for the function of compstatin peptides at molecular level, based on 
intermolecular contacts and energetic analysis. In particular, the MD structural data depict 
that Peptides III and VI form strong intermolecular salt bridges between arginine at positions 
1 or -1 and Glu372 of C3, which is an additional contributing factor to stability of the C 
Peptide complexes and to the steric hindrance mechanism for convertase binding. We expect 
that our data will form the basis for further optimization of these peptides, perhaps by 
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incorporating additional non-natural amino acids, in search of a more potent complement 
inhibitor for the treatment of AMD. 
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Figure 3.3. 
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Figure 3.5. Intermolecular contacts of Peptides III, VI, and IX with C3 from molecular 
dynamics simulations. Simulation structures of the C3 binding site with Peptides III (A, B), 
VI (C, D), and control Peptide IX (E, F) (Tamamis et al. 2010) at the end of the molecular 
dynamics simulations. Important hydrogen bonds and nonpolar binding pockets are shown, 
respectively, in the left and right panels. Five interacting C3 sectors (344 – 349; orange, 371 
– 376; green, 388 – 393; blue, 454 – 462; yellow, and 488 – 492; gray) with heavy atoms up 
to 7.5 Å from the Peptide VI ligand are shown in tube (A, C, E) and surface (B, D, F) 
representation. The purple lines in (A, C, E) denote important hydrogen bonds. All hydrogen 
atoms, except for those participating in hydrogen bonds (in A, C, E) are omitted for clarity. 
In panels (A, C, E) important main/side chain hydrogen bonding protein–ligand residue pairs 
are shown in licorice. In panels (B, D, F) important ligand side chain groups, lying on or 
binding into the protein surface, are shown in licorice. (For interpretation of the references to 
colour in this figure legend, the reader is referred to the web version of this article.) 
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Fig 3.6. Energetic analysis of intermolecular contacts of Peptides III and VI with C3 from 
molecular dynamics simulations. Two dimensional density maps depicting the favorable 
(negative) average MM GBSA interaction free-energies for intermolecular ligand (y axis) – 
C3 (x axis) interacting residue pairs, within the simulation of Peptides III (A, C) and VI (B, 
D) in complex with C3. The upper panels (A, B) correspond to polar interactions, and the 
bottom panels (B, D) correspond to nonpolar interactions. All energies are in kcal/mol. The 
color code for the interaction free energy is shown in the palette on the right-hand side of 
each panel. (For interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
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Tables 
Table 3.1. Compstatin peptide sequences. 
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Table 3.2. Compstatin peptide IC50 values from C3b and C5b-9 ELISA, and hemolytic 
assay 
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Figure 3.7. (S1). 
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Figure 3.8. (S2). 
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Figure 3.9. (S3). 
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Figure 3.10. (S4). 
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Chapter IV: 
 
Origin and Composition of Sub-cellular Deposits in a Cell Culture Model 
for Age-related Macular Degeneration 
Abstract 
The specific cellular and molecular mechanisms underlying retinal cell death in AMD remain 
poorly understood. Several different cell death pathways have been identified and 
experimentally induced in cultured RPE cells by oxidative stress and/or inflammatory 
stimuli. Apoptosis might be the source of the cytoplasmic debris accumulation that initiates 
drusen formation in AMD.  The present study was designed to simulate this aspect of AMD. 
Our initial goal was to determine the origin of cellular debris in a cell culture model of 
drusen formation.  We then determined if experimental chronic stress reliably induces the 
formation of sub-cellular apoptotic debris in vitro. We tested that hypothesis that apoptotic 
debris from RPE cells would contain drusen-related proteins and serve as a substrate for 
complement activation. In addition, we measured progression of cell death and found that 
prolonged stress creates regions of cell detachment similar to the patterns found in 
geographic atrophy, the end-stage condition of dry AMD. Finally, we tested the idea that 
cells would not grow normally on cell culture inserts that were pre-coated with cellular 
debris. The results indicate that RPE cell cultures undergo a similar form of atrophy under 
oxidative stress, serum deprivation, and high cholesterol conditions. Also, that drusen-related 
proteins (e.g. ApoE, Clusterin, and beta amyloid) are induced by stress, localize to the 
nucleus, and are delivered to the extracellular environment as apoptotic bodies. 
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Introduction 
 
Drusen, the characteristic lesions of AMD, are generally thought to be formed via the 
secretion of ‘undigested materials’ (e.g. membranous and cytoplasmic debris, lipids, etc.) 
from the RPE. Apoptosis of RPE might be the source of cytoplasmic debris accumulation 
that initiates drusen formation, and the question of “possible inflammatory consequences” of 
this process has been raised (Burns and Feeney-Burns 1980). Ishibashi et al. (1986b) also 
found sub-cellular debris in and around drusen from AMD patients. However, they did not 
use the term “apoptosis” because they did not observe separation of the plasma membranes 
from adjacent RPE cells, or condensation of the basal cytoplasm of the RPE cell before the 
onset of budding (Ishibashi et al. 1986b). Budding (i.e. “membrane blebbing”) is an early 
morphological feature of apoptosis and might be a pre-apoptotic cellular defense mechanism 
(Babiychuck et al. 2011).  Blebbing normally occurs before separation of the plasma 
membrane from neighboring cells. This shedding of RPE basal cytoplasm into Bruch’s 
membrane may be a way to discard damaged cytoplasm to bring about cell renewal. 
Although the budding and degradation of cytoplasmic material from the RPE is postulated to 
initiate drusen formation, the reason for budding, and subsequent RPE degeneration is 
unknown (Ishibashi et al. 1986a). Cellular stressors, such as oxidative stress, inflammation, 
and nutrient deprivation caused by accumulated debris, might contribute to the ongoing 
process of budding and cellular degradation observed in AMD. 
Morphological features of late stage apoptosis include the formation of apoptotic 
bodies, which involves nuclear and cytoplasmic condensation, nuclear fragmentation and the 
release of many membrane-bounded cell remnants of varying size (Kerr et al. 1972). Large 
apoptotic bodies frequently occur in clusters in the intercellular space, the smaller bodies 
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tend to disperse from their site of origin and remain extracellular. In vivo, the apical RPE 
surface interfaces with retinal photoreceptors and its basal surface attaches to Bruch’s 
membrane, a specialized structure composed of collagen, laminin, elastin, and fibronectin 
(Booij et al. 2010). This porous extracellular matrix (ECM) allows for selective metabolite 
exchange to occur between the retina and its primary blood supply, the choriocapillaris 
(Curcio and Johnson 2013).  In AMD, small discarded cytoplasmic pieces from RPE cells 
appear to fragment and disperse vesicular elements and membranes along the elastic lamina 
of Bruch’s membrane.  
The specific cellular and molecular mechanisms underlying retinal cell death in AMD 
remain poorly understood. Several different cell death pathways have been identified and 
experimentally induced in cultured RPE cells by oxidative stress and/or inflammatory 
stimuli. For example, the autophagic cell pathway is activated by tamoxifen in ARPE-19 
cells (Cho et al. 2012). FasL-mediated apoptosis of ARPE-19 cells is induced by 
lipopolysaccharides and hydrogen peroxide, H2O2 (Wang et al. 2012). Another study 
specifically implicated necrosis in the death of H2O2-treated ARPE-19 cells (Hanus et al. 
2013). In contrast, pyroptosis was identified as the primary cell death pathway in mouse 
retinal stem cells and ARPE-19 cells that were exposed to interleukins as inflammatory 
stimuli (Ardlejan et al. 2014).  
Apoptosis is one of the pathways of cell degeneration in AMD (Ge-Zhi et al. 1996). 
TUNEL labeling for nuclear fragmentation indicates that macular RPE apoptosis 
significantly increases in older human eyes (Del Priore et al. 2002). Also, most apoptotic 
RPE and photoreceptor cells are found at the edges of atrophic areas in eyes with geographic 
atrophy (Dunaief et al. 2002). TUNEL-positive apoptotic RPE in eye tissue from patients 
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with wet AMD occurs near drusen and is associated with apoptosis-inducing Fas and FasL 
expression (Hinton et al. 1998). In addition, a range of caspases have been theoretically 
linked to AMD development, including caspases 1, 3, 4, 5, 8, and 12. Caspase (cysteine-
dependent, aspartate-specific protease) activation ultimately results in apoptosis, dismantling 
of dying cells, and disposal of apoptotic bodies by phagocytes (Fadeel and Orrenius 2005). In 
the eye, for example, activation of innate immunity can damage retinal tissue, with cell death 
mediated by inflammatory cytokines (Ardeljan et al. 2014). Subsequent caspase-1 mediated 
cell death (pyroptosis), with excessive autophagy, extranuclear DNA, and mitochondrial 
function can result. Caspase-3 is involved in blue-light induced apoptosis of photoreceptors 
and RPE cells in the rat (Seko et al. 2001; Wu et al. 2002), human ARPE-19 cells (Sparrow 
and Cai 2001), and is also associated with p53-mediated apoptosis in human primary RPE 
cell cultures (Bhattacharya et al. 2012). Various pro-inflammatory stimuli and ER stress 
induce caspase-4 activation in human primary RPE cultures (Bian et al. 2009). However, the 
relationship between caspase activation and the development of AMD remains unclear. 
The controlled ingestion of apoptotic cells by phagocytes (e.g. dendritic cells) 
normally conveys a “do not attack self” message to the immune system. However, a ‘pro-
immune meaning’ can be conferred on the phagocytosis of dying cells by dendritic cells 
when there is defective clearance of apoptotic debris (Savill and Fadok 2003). For example, 
apoptotic cells are a major source of autoantigens in SLE (Systemic Lupus Erythematosus) 
and impairment of their physiological clearance may promote the development of 
autoimmunity (Taylor et al. 2000). A similar process may occur in AMD. Cynomolgus 
monkeys that experience macular degeneration and develop drusen have elevated levels of 
circulating anti-annexin antibodies (Umeda et al. 2005). Sera from human AMD patients also 
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show elevated levels of autoimmune anti-retinal antibodies (Patel et al. 2005, Iannaccone 
2012)   
Complement binds to, and helps eliminate, cells that have undergone apoptosis. It 
binds apoptotic and necrotic cells and may serve as an opsonin for cell fragments that have 
escaped regular scavenging mechanisms (Gaipl et al. 2001). If the complement system fails 
at this point, apoptotic waste material (consisting of partially degraded components of the 
cytoplasm and nucleus) could accumulate and evoke an autoimmune response. Failure to 
clear autoantigens (defective waste disposal) may be the stage at which complement 
deficiency may have a pathogenic role (Mackay and Rosen 2001). C1q directly binds 
apoptotic cells and activates the classical complement pathway, but amplification via the 
alternative pathway is required for efficient recognition by macrophages. Thus, deficiencies 
in the alternative and early components of the classical complement pathways can result in 
the impaired clearance of dying cells (Mevorach et al. 1998). Dying cells escaping clearance 
provides danger signals to the immune system, and this mechanism might underlie the 
progression of AMD (Adler et al. 1999).  
The present study was designed simulate this aspect of AMD. The goal was to 
determine the origin of sub-cellular deposits found in a cell culture model for drusen 
formation. Our hypothesis was that the deposits are the remnants of apoptotic RPE cells. We 
determined that several drusen-related proteins localize to the nucleus, which degrades 
during apoptosis, and are delivered to the extracellular environment on apoptotic bodies. We 
also investigated the patterns of RPE cell death under oxidative stress, serum withdrawal, and 
high cholesterol conditions. In addition, we show that RPE cells grown on artificially 
produced “apoptotic debris” never attain a normal morphology. 
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Methods 
Human fetal RPE cells were seeded onto 25 g/ml laminin-coated cell culture inserts 
(Cat# PIHA 01250, Millicell HA Culture Plate Inserts, Millipore), cultured at 37°C with 5-
7% CO2. Cells were maintained in Miller medium containing 5% heat-inactivated fetal calf 
serum (Maminishkis et al. 2006). Apoptosis was induced by various methods including 1) 
Daily exchange of Miller medium containing 300 M hydrogen peroxide (Cat# 216763, 
Sigma Aldrich), 2) Medium plus 100 M cholesterol (22(R) Hydroxycholesterol, Cat# 
H9384, Sigma Aldrich), or 3) Prolonged nutrient deprivation via Miller medium without fetal 
calf serum. Experimental conditions were maintained for up to four weeks and sampled at 
various time points.  Apoptosis and secondary necrosis was visualized with the Alexa Fluor 
488 Annexin V/Dead Cell Apoptosis Kit (Cat# V13241, Molecular Probes/Life 
Technologies). Unfixed cells were labeled according to the provided experimental protocol 
using 10 l of Annexin V and 1 l of Propidium Iodide working solution per 100 l of 
staining solution for 15 minutes at room temperature.  For immunohistochemistry, RPE cell 
cultures were fixed in 4% paraformaldehyde for 20 minutes and blocked with normal donkey 
serum (1:20) overnight. Primary and secondary antibodies were diluted in PBS with 0.5% 
Triton-X and incubated at 4°C overnight. Digital images were taken with an Olympus FV 
1000 confocal microscope. To determine the effect that sub-cellular deposits have on RPE 
cultures, cells were plated on debris-coated Millipore HA inserts. Cell debris was created by 
taking one entire insert from confluent cultures and grinding it in a tissue homogenizer. The 
lysate was mixed with 25 g/ml laminin in PBS and used to coat inserts for one hour at room 
temperature. Inserts were then rinsed in PBS and new cells were plated on the laminin/debris 
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mixture. Control cells were plated as usual on laminin-only coated inserts. All cultures were 
grown for 4 weeks then treated with human serum, as a source of activated complement, 
overnight. Immunohistochemistry for ApoE and C5b9 was performed as previously 
described (Johnson et al. 2011).  
 
Results 
Origin of sub-cellular deposits in RPE cell cultures 
One of the aims of this study was to discover the mechanism by which sub-cellular 
deposits spontaneously form in a cell culture model of drusen formation. To test the 
hypothesis that deposits are apoptotic bodies, RPE cells were seeded onto laminin-coated 
inserts, cultured under normal, non-stressed conditions, sampled at various time points (days 
3, 10 and 20 post-seeding), and labeled with Annexin V. This fluorescent compound 
normally binds phosphatidyl serine that is exposed on the outer membrane of cells 
undergoing apoptosis and secondary necrosis. We used it to label the membrane-containing 
debris that becomes trapped within the insert material.  
Results from two hfRPE cell lines reveal cells in various stages of apoptotic 
disintegration. Some of the cells apparently undergo apoptosis soon after seeding. By 3 days 
post-seeding, patches of membranous debris can be seen within the matrix of the cell culture 
insert (Figure 1). By day 10, Annexin V labeling is apparent on a subset of cells. As viable 
cells become confluent, the debris becomes overgrown and sequestered beneath the cells 
(Figure 2). By day 20, the cells approach confluence and apoptosis becomes restricted to 
isolated cells. Scattered clusters of apoptotic bodies remain as sub-cellular deposits (Figure 
3). 
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Creating deposits in vivo 
To determine if sub-cellular apoptotic bodies could be experimentally created, cells 
were subjected to serum withdrawal for two weeks then stained with Annexin V and 
Propidium Iodide (PI) which stains DNA in necrotic cells. Cells grown on Millipore HA 
inserts were embedded in agarose and sectioned on a vibratome (Johnson et al. 2011). 
Cellular disintegration following secondary necrosis is shown in Figure 4. Although the 
various conditions were all found at the same two-week time point, the following sequence 
of events was inferred from the images. Annexin V and PI positive cells disintegrate and 
begin to dissociate from the cell culture insert (Figure 4A). As necrosis progresses, Annexin 
V labeled membranous debris becomes trapped within the porous support matrix (Figure 
4B). Finally, after the cells become detached, apoptotic bodies remain clustered within the 
pores of the cell culture insert (Figure 4C). 
High cholesterol levels can induce apoptosis in cultured cells and is also associated 
with the development of AMD (Dasari et al. 2011, George et al. 2012). To investigate the in 
vitro effects of cholesterol on RPE cells, Miller medium with cholesterol (final concentration 
100 M) was administered to hfRE cell line 3914 for one week. Cell death was assessed via 
Annexin V/PI labeling and confocal microscopy. Experimental controls included chloroform 
only (no cholesterol), and normal conditions (Miller medium + fetal calf serum). The percent 
area of Annexin V positive pixels was assessed in order to quantify differences among 
treatments. Representative images from the three conditions are shown in Figure 5 and 6. 
Image analysis indicates a nearly four-fold increase in the cholesterol treated cells relative to 
the chloroform control, and a greater than two-fold increase in the cholesterol treated cells 
relative to normal culture conditions. There was significantly more Annexin V labeling in the 
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high cholesterol condition compared to the vehicle (chloroform) only control (t-test, p=0.042, 
n = 5 per condition) (Figure 7). 
 
Patterns of RPE cell death under stressed conditions 
RPE cell cultures appear to undergo a similar pattern of cell death regardless of the 
stressor. Under normal culture conditions, a few isolated cells and cell clusters will typically 
undergo apoptosis (Figure 8). Serum-deprived cells develop small clusters of Annevin V 
labeled cells (Figure 9A) that progress into expanding regions of atrophy containing Annexin 
V and PI labeled cellular debris (Figure 9B). In addition to debris, Annexin V/PI labels cells 
at the edges of the expanding lesion areas (Figure 9C). With continued stress, the ‘geographic 
atrophy-like’ lesions grow into large cellular graveyards containing the apoptotic bodies from 
dead and dying RPE cells (Figure 9D). A similar pattern of apoptosis and lesion growth is 
seen in cells under oxidative stress (300 uM H2O2) for fourteen days (Figure 10). Annexin 
V/PI labeling reveals the progression of cell death around expanding areas of atrophy and 
debris (Figure 11).   
 
Localization of drusen-related proteins 
Results from this experiment show that cultured RPE cells accumulate amyloid 
precursor protein (APP)/Amyloid beta (A) in the nucleus under serum-deprived and 
oxidative stress conditions. Increased cytoplasmic Alpha B crystalline also appears with 
nuclear amyloid in serum-deprived cells (Figure 12A). In addition, upregulation of 
cytoplasmic and nuclear APP/A is apparent in a number of cells (Figure 12B). An A 
specific antibody (Rinat 7G10, data not shown) reveals nuclear localization on cells that were 
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not subjected to human serum, implying an RPE source of A. Amyloid is localized on 
nuclear waste material in an area of cellular debris, which also contains ApoE (Figure 12C). 
ApoE and ApoJ/Clustrin co-localize in the nucleus of dying cells and cell debris from 
(081309) cells under oxidative stress for 2 weeks (Figure 13). ApoE can appear to be more 
cytoplasmic or nuclear-related under stress conditions. It is possible that ApoE is upregulated 
and becomes cytoplasmic and then subsequently becomes localized to the nucleus as 
apoptosis proceeds. It is unknown whether this is a result of stress condition, difference in 
time point, or stage of apootosis. Although not a documented drusen-related protein, Caspase 
3-cleaved APP (C31) is found on debris from serum deprived cells (Figure 12D). However, 
the C31 labeled apoptotic bodies do localize with C5b9, a drusen-related marker of 
complement system activation. 
 
RPE cells grown on debris never attain a normal morphology  
Cells grown on the experimentally created “apoptotic bodies” do not attain a normal 
RPE morphology. Normal RPE cultures grow into a uniform monolayer with no cytoplasmic 
or nuclear ApoE expression (Figure 14A). However, the cells exposed to debris have a 
flattened, mesenchymal appearance. The cells tend to overgrow each other and become 
multi-laminar. Also, the cells have increased levels of cytoplasmic ApoE immunoreactivity 
(Figure 14 B-D). In addition, some cells growing over cellular debris appear de-pigmented 
and have drusen-like concentrations of sub-ApoE and C5b9 immunoreactive cellular deposits 
(Figure 15).  
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Discussion 
RPE apoptosis normally occurs during embryogenesis, and is a critical factor in 
retinal optic cup development (Pequignot et al. 2011). Like macrophages, RPE cells act as 
phagocytes to dispose of apoptotic debris from neighboring cells (Petrovski et al. 2011). This 
ability depends on ATP and can be compromised by oxidative stress (Schutt et al. 2012). In 
turn, oxidative stress can make RPE cells susceptible to complement attack (Thurman et al. 
2009). In addition to its role in complement attack, terminal complement complexes (C5b9) 
on stressed cells also activate caspase-3 (Nauta et al. 2002). The present study demonstrates 
that apoptosis normally occurs early in RPE cell culture, and that apoptotic bodies remain as 
sub-RPE deposits within the porous supporting matrix of the cell culture insert. Similar 
deposits were previously shown to contain several drusen-related proteins, including ApoE, 
ApoJ, and C5b9, after exposure to human serum as a complement source (Johnson et al. 
2011). Cells growing on cellular debris created from homogenized RPE never attain a normal 
morphology. Cell signaling molecules that are not found in apoptotic bodies are likely 
present in this type of artificially created ‘necrotic’ debris.  
Apolipoprotein E (ApoE) is found in the extracellular deposits associated with several 
disorders, including Alzheimer’s disease (AD) Atherosclerosis, and AMD. It is a common 
component of drusen and is also known to be produced by RPE cells. Elevated cytoplasmic 
ApoE expression was shown in RPE cells overlying drusen in vivo (Anderson et al. 2001).  
ApoE is associated with lipid trafficking and is known to transport cholesterol. Elevated 
cholesterol levels induce ApoE secretion in primary glial cells and a mouse model of AD 
(Petanchesca et al. 2003). Primary RPE cultures also upregulate ApoE secretion in response 
to several compounds, including 22(R)-hydroxycholesterol (Ishida et al. 2004).  
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The present study also demonstrates cytoplasmic ApoE upregulation and, in addition, 
nuclear localization in cultured RPE cells under experimental conditions. Although the 
precise role is unclear, nuclear ApoE localization may be found in various cell types (e.g. 
CHO cells and human fibroblasts) under stress conditions such as serum starvation (Quinn et 
al. 2004, Kim et al. 2008). During nutrient withdrawal, ApoE and caspase-3 are upregulated 
during neuronal apoptosis, with ApoE becoming increasingly concentrated in apoptotic 
bodies (Elliot et al. 2007). ApoE also modulates macrophage uptake of apoptotic bodies and 
may act as a signaling mechanism to promote clearance of apoptotic debris (Grainger et al. 
2004).   
Proteolysis of amyloid precursor protein (APP) by secretases and caspases creates 
various peptide fragments, including beta amyloid (A). Although the role of A in AMD 
pathogenesis and drusen formation is unknown, it is often found near degenerating 
photoreceptors and RPE cells (Dentchev et al. 2001). Upon serum deprivation, primary 
human neuron cultures undergo apoptosis and significantly increase their production of A 
(LeBlanc 1995). Co-deposition of molecules such as ApoE, ApoJ, C5b9, and A in drusen 
may indicate attempts to inhibit aggregation or promote clearance of A in the extracellular 
space (Anderson et al. 2004, Hao et al. 2010). The present study suggests that co-deposition 
of proteins occurs on degrading RPE cell nuclei which are subsequently delivered to the 
extracellular environment as apoptotic bodies.  In addition to A, caspase cleavage of APP 
leads to production of an intracellular C-terminal domain involved with cell signaling (Zhang 
et al. 2012).  Caspase cleavage of APP also creates pro-apoptotic C-terminal fragments, 
including C31 (Bertrand et al. 2001, Pellegrini et al. 1999). In neurons, upregulation of APP 
induces a C31/caspase-3 feedback loop that acts as a cell death signal (Nishimura et al. 
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2002.) In cultured mouse neuroblastoma cells, C31 is translocated to the nucleus to induce 
apoptosis-related gene expression (Shaked et al. 2006).  Caspase 3 activity co-localizes with 
APP cleavage products and A in AD-related plaques and cultured rat retinal ganglion cells 
(McKinnon et al. 2002). This study also provides evidence for caspase-3 involved apoptosis 
and APP processing in RPE cells. ApoE and processed APP may be involved in the 
systematic degradation of nuclear material during RPE cell death. It remains to be 
determined if ApoE and A in drusen are the degraded remnants of such nuclear debris.  
The goals of this study were to determine the role of apoptosis in the accumulation of 
cellular debris, and to investigate the in vitro pattern of RPE cell death and complement 
activation induced by cellular stressors (e.g. oxidative stress and serum withdrawal) in a cell-
culture model for drusen formation. It remains to be determined which of the several cell 
death pathways underlie the pathology of AMD, as well as the RPE cells used in this study. 
Several hfRPE cell lines were used in these experiments, which may be a source of variation 
in the results. Further studies might include TUNEL labeling, pan-caspase assays, and PCR 
cell death arrays on cultured cells and tissue from AMD patients. Multiple cell death 
pathways can run simultaneously and share responsibility for photoreceptor cell death in 
mouse models of Retinitis Pigmentosa (Fong and Tsilfidis 2012). Thus, the patterns of cell 
death observed in complex conditions such as geographic atrophy may result from multiple 
cell death pathways acting in parallel.  
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Figures: 
 
 
 
Figure 4.1.  Annexin V labels cellular debris. hfRPE cells 3 days after plating on laminin-
coated Milllipore HA insert. Annexin V positive cells shedding debris into the extracellular 
environment (arrows). Cell line 081309 (A and B, magnification) and 072810 (C and D, 
magnification). Annexin V (green), DNA/Hoechst (blue); Scale bar = 10 m. 
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Figure 4.2. Annexin V labels cellular debris. hfRPE cells 10 days after plating on laminin-
coated Milllipore HA insert. Continued cellular disintegration (arrows) and overgrowth of 
debris as cells approach confluence.  Cell line 081309 (A and B, magnification) and 072810 
(C and D, magnification). Annexin V (green) and the DNA/ Hoechst (blue). Scale bar = 10 
m. 
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Figure 4.3. hfRPE cell line 081309 (A and B, magnification) and 072810 (C and D, 
magnification) 20 days after plating on Milllipore HA insert. Cells become confluent and 
sub-RPE apoptotic bodies (arrows) remain in the porous material of the insert. Annexin V 
(green), DNA (blue). Scale bar = 10 m. 
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Figure 4.4. Sub-cellular deposit formation in serum-deprived RPE cell cultures (hfRPE cell 
line 3914, in culture for 10 months). Annexin V (green) and PI (arrows, red) labeled cellular 
debris accumulates within the support matrix (indicated by asterisk in A). Various stages of 
secondary necrosis and disintegration of RPE cells co-occur following 14 days of serum 
deprivation. Necrotic cells with Annexin V labeled cell membrane and PI labeled nuclei (A) 
continue to disintegrate (B) until only areas of cellular debris and cell detachment remain 
(C). Scale bar = 10 m. 
 
 
 
 
  
 
 
 
 
 
A
 
 
A 
B
 
 
A 
C
 
 
A 
 
 
* 
132 
 
Cholesterol [100 uM] 1 week: 
 
Chloroform only control: 
 
 
Figure 4.5. Representative images from cholesterol exposure experiment (hfRPE cell line 
3914, in culture for 8 weeks). Exposure to 100 uM cholesterol in Miller medium for 1 week 
causes a nearly 4-fold increase in Annexin V labeling. Necrotic nuclear material, which 
stains with both PI and Hoechst (purple), and cell membrane debris accumulates in ‘lesion’ 
areas (* in A and B).   Annexin V (green), PI (red), DNA (blue). Scale bar = 20 m. 
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Normal conditions control: 
 
 
 
Figure 4.6. Representative images from normal cell culture conditions (3914 cells, in culture 
8 weeks). Scale bar = 20 m. Annexin V (green), PI (red) DNA (blue). 
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Treatment % Pixel area S.E.M 
100 uM Cholesterol 
Chloroform control 
Normal control 
9.139 
2.399 
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0.666 
 
Figure 4.7. Image analysis of Annexin V pixel area. Data from hfRPE cell line 3914 
indicates an approximately three- to four-fold increase in Annexin V labeling in the 
cholesterol treated cells vs. the controls. A significant difference was found between the 
cholesterol and chloroform control (t-test, p=0.042, n = 5 images per condition). Error bars = 
1 S.E.M. 
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Figure 4.8. Typical pattern of apoptosis under normal cell culture conditions (cell lines 
012109 and 081309, in culture 5 weeks). Relatively few isolated cells are labeled with 
AnnexinV in confluent cultures 5 weeks post-seeding. Annexin V (green) with transmitted 
light (A), and Hoechst (B, blue). Scale bar = 10 m (A), 20 m (B). 
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Figure 4.9. Patterns of cell death in serum-deprived RPE cell cultures (cell line 3914, 7 
months in culture). Various stages of atrophy are seen after serum deprivation. After 1 week, 
small clusters of AnnexinV labeled cells are seen (A). By 2 weeks, clusters grow into patches 
of atrophy bordered by necrotic cells (B). Larger areas of atrophy (C and D) become littered 
with membranous and nuclear debris. Annevin V (green), PI (red). Scale bar = 20 m. 
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Figure 4.10. Under normal conditions (4 weeks post-seeding) relatively few cells undergo 
apoptosis (Arrows in A and B). 14 days of hydrogen peroxide-induced oxidative stress 
conditions results in increased Annexin V (green) clusters and regions of cell detachment 
containing residual debris (arrows in C and D). Cell line 081309, scale bar = 20 m. 
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Figure 4.11. Oxidative stress-induced atrophy around debris field (cell line 081309, 4 weeks 
in culture plus 2 weeks of stress A, B, and 3 weeks of stress C, D). Annexin V (green), PI 
(red , D). Scale bar = 20 m.  
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Figure 4.12.  Localization of drusen-related proteins in serum deprived 020207 cells (in 
culture 8 weeks). A. Alpha B Crystalin (green), A/APP (red), DNA (blue). B. A/APP 
(red), DNA (blue). C. ApoE (green), A/APP (red), DNA (blue). D. C31 (Caspase 3-cleaved 
APP(green) with C5b9 (red). Scale bar = 20 m (A-C), 10 m (D). 
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Figure 4.13. Nuclear localization of drusen-related proteins under oxidative stress conditions 
(cell line 081309, in culture 8 weeks).  Cells were exposed to 14 days of oxidative stress, not 
exposed to human serum. Thus, indicating a cellular source of ApoE (red, A) and 
ApoJ/Clustrin (green, B), overlay (C). Scale bar = 15 m.   
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Figure 4.14. Normal (A) and abnormal (B-D) hfRPE cell morphology in culture. Typical 
RPE cells grow into a uniform monolayer (A, 3914 cells in culture 8 weeks). ApoE (red) and 
C5b9 (green) immunohistochemistry labeling is restricted to the sub-cellular deposits formed 
early in cell culture. Cells grown on inserts plated with debris have a flattened appearance, 
overgrow each other, and have elevated cytoplasmic ApoE levels (B-D). Scale bar = 10 m. 
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Figure 4.15. Depigmented RPE cells over drusen-like debris (3914 cells in culture 8 weeks). 
ApoE immunolocalization in sub-cellular debris and overlying cells (arrows).  ApoE (red), 
C5b9 (green), DNA (blue). Scale bar = 5 m 
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